aspirin and prasugrel hydrochloride

aspirin has been researched along with prasugrel hydrochloride in 350 studies

Research

Studies (350)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	50 (14.29)	29.6817
2010's	230 (65.71)	24.3611
2020's	70 (20.00)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Asai, F; Jakubowski, JA; Niitsu, Y; Sugidachi, A	1
Brandt, JT; Darstein, C; Jakubowski, JA; Jernberg, T; Naganuma, H; Payne, CD; Siegbahn, A; Wallentin, L; Winters, KJ	1
Lowry, DR; Malinin, AI; Meilman, H; Midei, MG; Serebruany, VL	1
Gurbel, PA; Tantry, US	3
Bliden, KP; Gurbel, PA; Tantry, US	1
Brandt, JT; Farid, NA; Jakubowski, JA; Lachno, DR; Li, YG; Naganuma, H; Payne, CD; Weerakkody, GJ; Winters, KJ	1
Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Jakubowski, JA; Li, Y; Linden, MD; Michelson, AD; Sugidachi, A; Winters, KJ	1
Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD	1
Bhatt, DL	1
Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Siegbahn, A; Sugidachi, A; Varenhorst, C; Wallentin, L; Winters, KJ	1
Brandt, JT; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	2
Paulus, W; Riggert, J; von Lewinski, F	1
Eikelboom, JW; Hankey, GJ; Langton, PE	1
Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD	1
Barker, CM; Price, MJ	1
Angiolillo, DJ; Bass, TA; Bates, ER	1
Abbate, R; Gensini, GF; Gori, AM; Marcucci, R	1
Cohen, M; Giugliano, R; Granger, CB; Gurbel, PA; Hoekstra, J; Hollander, JE; Manoukian, SV; Pollack, CV; Saucedo, JF	1
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Johnell, M; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ	1
Wiviott, SD	1
Eikelboom, JW; Hirsh, J; Raju, NC	1
Ernest, CS; Rohatagi, S; Salazar, DE; Small, DS; Wallentin, L; Winters, KJ; Wrishko, RE	1
Calatzis, A	1
Kopyleva, O; Serebruany, V; Shalito, I	1
Toth, PP	1
Faxon, DP; Freedman, JE	1
Brandt, JT; Braun, OO; Erlinge, D; Jakubowski, JA; James, S; Olofsson, S; Siegbahn, A; Varenhorst, C; Wallentin, L; Winters, KJ	1
Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD	1
Antonino, MJ; Gurbel, PA; Mahla, E; Tantry, US	1
Butt, M; Lip, GY; Shantsila, E; Siddique, A	1
Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ	1
Cryer, B	1
Das, K; Das, P; Koshy, SK; Robinson, A	1
Price, MJ	1
Motovska, Z; Widimsky, P	1
Shil, AB; Strohm, MP	1
Barthélémy, O; Beygui, F; Collet, JP; Funck-Brentano, C; Hulot, JS; Montalescot, G; Pena, A; Silvain, J	1
Serebruany, VL	2
Eberli, FR; Roffi, M	1
Alban, S; Dingermann, T	1
Breitkreutz, J	1
Kumar, A; Roberts, DH	1
Dauerman, HL	1
Antman, EM; Braunwald, E; Buros, JL; Gibson, CM; Pride, YB; Tariq, MU; Wiviott, SD; Zorkun, C	1
Unger, EF	1
Ernest, CS; Farid, NA; Li, YG; Ni, L; Payne, CD; Salazar, DE; Small, DS; Winters, KJ; Wrishko, RE	1
Collet, JP; Montalescot, G	1
Menon, V; Raymond, C	1
Solomon, S; Vacek, JL	1
Islam, AM; Patel, PM	1
Fareed, J; Jeske, WP; Mousa, SA	1
Aylward, PE; Behan, MW; Chew, DP	1
Bareiss, P; Kessler, L; Morel, O; Ohlmann, P	1
Chew, DP; Prakash, R; Wong, YW	1
Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A	1
Erdem, G; Flather, MD; Geisler, T	1
Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS	1
Gratsianskiĭ, NA	1
Aïssaoui, N; Danchin, N	1
Gurbel, PA; Mahla, E; Metzler, H; Tantry, US	1
Abbate, R; Giusti, B	1
Laizure, SC; Parker, RB	1
Ferrandis, R; Gómez-Luque, A; Llau, JV; Sierra, P	1
Abraham, NS; Antman, EM; Bhatt, DL; Bjorkman, DJ; Clark, CB; Furberg, CD; Hlatky, MA; Johnson, DA; Kahi, CJ; Laine, L; Mahaffey, KW; Quigley, EM; Scheiman, J; Sperling, LS; Tomaselli, GF	2
Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C	1
Minarelli, M; Valgimigli, M	1
Frey, N; Ivandic, B	1
Ağırbaşlı, M; Cinçin, A; Güvenç, H	1
Endres, HG; Engelhardt, A; Kaiser, AF; Krüger, JC; Kusber, A; Lask, S; Mügge, A; Neubauer, H; Pepinghege, F	1
Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B	1
Cattaneo, M	1
Engelen, S; Sinnaeve, P; Van Damme, H; Verhamme, P	1
Hamm, CW; Rassaf, T	1
Smetana, GW; Srour, JF	1
Baty, SR; Griffith, CB; Phillippe, HM	1
Briongos Figuero, S; de Juan-Bagudá, J; Martí-Sánchez, D; Salido-Tahoces, L	1
Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD	1
Moliterno, DJ; Rajan, L	1
Dhanji, AR; Kirkby, NS; Leadbeater, PD; Milne, GL; Mitchell, JA; Thomas, S; Tucker, AT; Warner, TD	1
Chan, MV; Kirkby, NS; Leadbeater, PD; Mitchell, JA; Nylander, S; Warner, TD	1
Bonafede, M; Deitelzweig, SB; Gdovin Bergeson, J; Graham, J; Jing, Y; Liffmann, D; Makenbaeva, D	1
Rayoo, R; Sharma, N; van Gaal, WJ	1
Chen, SY; Gao, H; Ma, GF	1
Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J	2
Bae, JP; Cohen, DJ; Graham, JB; Magnuson, EA; Mauskopf, JA; Meadows, ES; Ramaswamy, K; Zagar, AJ	1
Basra, SS; Lakkis, NM; Tsai, P	1
Barakoti, M; Neupane, P; Pant, S; Ramesh, KC	1
Ikeda, Y; Isshiki, T; Kimura, T; Ogawa, H; Yokoi, H	1
Braunwald, E	1
Hsu, PI	1
Contractor, H; Ruparelia, N	1
Amore, C; Dell'Elba, G; Di Santo, A; Evangelista, V; Martelli, N; Piccoli, A; Totani, L	1
Angiolillo, DJ; Azmoon, S	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Paganelli, F; Uhry, S	1
Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ	1
Gupta, A; Hirst, J; McKay, RG; Rai, M; Ruaño, G; Seip, RL; Thompson, PD	1
Heptinstall, S; Joshi, R; Wijeyeratne, YD	1
Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ	1
Ahmad, S; Storey, RF	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A	1
Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY	1
Limper, U; Lynch, J	1
Huber, K	1
Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ	1
Choi, KN; Chung, SR; Do, U; Jang, JS; Jin, HY; Kim, DK; Kim, DS; Kim, HJ; Seo, JS; Yang, TH	1
Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C	1
Abtan, J; Aubry, P; Barthélémy, O; Belle, L; Beygui, F; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Elhadad, S; Henry, P; Kerneis, M; Monségu, J; Montalescot, G; Motreff, P; O'Connor, SA; Pouillot, C; Rangé, G; Rousseau, H; Sabouret, P; Saint-Etienne, C; Silvain, J; Van Belle, E; Vicaut, E	1
Badimon, JJ; Elmariah, S; Fuster, V; Giannarelli, C; Jakubowski, JA; Santos-Gallego, C; Sartori, S; Small, DS; Viles-Gonzalez, JF; Vorchheimer, DA; Zafar, MU	1
Chevalier, B; Diletti, R; Dorange, C; Farooq, V; Garcia-Garcia, HM; Miquel-Hebert, K; Onuma, Y; Rapoza, R; Serruys, PW; Sudhir, K; Veldhof, S	1
Coste, P; Gerbaud, E; Seguy, B	1
Kiss, RG	1
Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R	1
Crosby-Nwaobi, R; Drozdov, I; Dudek, K; Kaudewitz, D; Kiechl, S; King, A; Kirkby, NS; Langley, SR; Markus, HS; Mayr, M; Mitchell, JA; Prokopi, M; Sivaprasad, S; Warner, TD; Willeit, P; Zampetaki, A	1
Can, MM; Dinicolantonio, JJ; Goto, S; Serebruany, VL	1
Aronow, WS	2
Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S	1
Kastrati, A; Martischnig, A; Mayer, K; Mehilli, J; Sarafoff, N; Sibbing, D; Wealer, J	1
Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US	1
Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K	1
Angiolillo, DJ; Bailey, WL; Baker, BA; Bliden, KP; Gurbel, PA; Jakubowski, JA; Jeong, YH; Kereiakes, DJ; Lasseter, KC; Logan, DK; Maa, JF; Nolin, TD; Ojeh, CK; Tantry, US; White, A	1
Gremmel, T; Kopp, CW; Koppensteiner, R; Panzer, S; Seidinger, D; Steiner, S	1
Franken, CC; Kaiser, AF; Krüger, JC; Mügge, A; Neubauer, H; Overbeck, K	1
Apostolakis, S; Lip, GY; Shantsila, E	1
Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ	1
Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL	1
Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Franchi, F; Guzman, LA; Muñiz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Thano, E; Wilson, RE	1
Dinicolantonio, JJ; Norgard, NB	1
Aslam, R; Ducrocq, N; Gerard, A; Kimmoun, A; Levy, B; Perez, P; Thivilier, C	1
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G	1
Grove, EL; Würtz, M	2
Curkovic, I; Egbring, M; Kullak-Ublick, GA	1
Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD	1
Adsett, G; Jayasinghe, R; Markham, R	1
Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD	1
Angiolillo, DJ; Bass, TA; Darlington, A; Desai, B; Ferreiro, JL; Guzman, LA; Patel, R; Rollini, F; Tello-Montoliu, A; Ueno, M	1
Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M	1
Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Price, MJ	1
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C	1
Ay, C; Badr Eslam, R; Eichelberger, B; Gremmel, T; Lang, IM; Panzer, S; Posch, F	1
Henke, C; Strasser, RH; Wiedemann, S	1
Alexander, T; Babu, PR; Dani, S; Dasbiswas, A; Hiremath, S; Nayak, R; Patel, T; Pathak, K; Prakash, VS; Rao, MS; Singh, DP; Srivastava, A; Tyagi, S; Vijayvergiya, R; Yadav, MK	1
Hirschl, MM	1
Gupta, K; Singh, D; Vacek, JL	1
Duraj, L; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Staško, J	1
Brennan, T; Choudhri, OA; Do, HM; Dodd, RL; Marcellus, ML; Marks, MP; McTaggart, RA; Steinberg, GK	1
Al-Attar, N; Amour, J; Ascione, R; Collet, JP; Falk, V; Huber, K; Leite-Moreira, AF; Sousa-Uva, M; Storey, R; Taggart, D	1
Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H	1
Bangalore, S; Biondi-Zoccai, G; Cerrato, E; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Fuchs, FD; Lavie, CJ; Meier, P; Niazi, AK; Norgard, NB; O'Keefe, JH; Packard, KA; Serebruany, VL	1
Gislason, G; Sørensen, R	1
Corrada, E; Ferri, M; Savonitto, S	1
Droppa, M; Gawaz, M; Geisler, T; Karathanos, A; Metzger, J; Müller, K; Rath, D; Schäffeler, E; Schwab, M; Stimpfle, F; Tavlaki, E; Winter, S	1
Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Gensini, GF; Giurlani, L; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R	1
Abtan, J; Anzaha, G; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Charland, SL; Collet, JP; Galier, S; Gallois, V; Hulot, JS; Kerneis, M; Montalescot, G; O'Connor, SA; Silvain, J; Stanek, EJ	1
Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R	1
Fauchère, I; Schreiber, P; Wyss, C	1
Vengoechea, F	1
Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M	1
Bajkin, BV; Bajkin, IA; Petrovic, BB; Stankov, KM; Urosevic, IM	1
Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM	1
Chieffo, A; Colombo, A	1
Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW	1
Allocco, DJ; Christen, T; Garratt, KN; Jenkins, RG; Kereiakes, DJ; Lee, DP; Mauri, L; Pow, TK; Weaver, WD; Winters, KJ	1
Collet, JP; Montalescot, G; Silvain, J	1
Alber, H; Buser, P; Conen, D; Eberli, F; Galatius, S; Gilgen, N; Hoffmann, A; Jeger, R; Kaiser, C; Kurz, DJ; Moccetti, T; Müller, C; Naber, C; Pedrazzini, G; Pfisterer, M; Rickenbacher, P; Rickli, H; Skov Jensen, J; Steiner, M; Vogt, DR; Von Felten, S; Vuillomenet, A; Wadt Hansen, K; Wanitschek, M; Weilenmann, D	1
Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L	1
Lhermusier, T; Waksman, R	1
Bultas, J	1
Harris, K; Kebbe, J	1
Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R	1
Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S	1
Jakubowski, JA; Mizuno, M; Ohno, K; Sugidachi, A; Tomizawa, A	1
Steg, PG; Wiviott, SD	1
Bernardo, E; Fernández, C; Fernández-Ortiz, A; Macaya, C; Martín, A; Núñez-Gil, I; Ortega-Pozzi, MA; Tirado, G; Vilacosta, I; Vivas, D	1
Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Kim, YD; Lee, YS; Park, JS; Park, K; Park, TH	1
Boyce, JA; Laidlaw, TM	1
Guimarães, PO; Tricoci, P	1
Armstrong, PC; Chan, MV; Finsterbusch, M; Hoefer, T; Kirkby, NS; Warner, TD	1
Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M	1
Assali, A; Greenberg, G; Kornowski, R; Lev, EI; Perl, L; Sasson, L; Vaknin-Assa, H; Weissler-Snir, A	1
Kim, YS; Lee, SR	1
Auffret, V; Avez, B; Bacquelin, R; Bedossa, M; Boulanger, B; Boulmier, D; Castellant, P; Coudert, I; Druelles, P; Filippi, E; Gilard, M; Hacot, JP; Le Breton, H; Le Guellec, M; Leurent, G; Moquet, B; Oger, E; Rialan, A; Rouault, G; Treuil, J	1
Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Tanaka, Y; Yokoi, H	1
Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Serebruany, VL	1
Armstrong, PC; Chan, MV; Kirkby, NS; Knowles, RB; Lundberg, MH; Mitchell, JA; Mohamed, NA; Tucker, AT; Warner, TD	1
Bougouin, W; Cariou, A; Dumas, F; Gouffran, G; Jakamy, R; Joffre, J; Lamhaut, L; Rosencher, J; Varenne, O	1
Dobesh, PP; Doyle, M; Varnado, S	1
Baker, BA; Cohen, DJ; Effron, M; Jackson, LR; Ju, C; Messenger, JC; Peterson, ED; Stone, GW; Wang, TY; Zettler, M	1
Ahn, DJ; Han, DK; Joung, YK; Jung, JW; Lih, E	1
Chong Tou, TJ; Lei Put, PZ; Lei Sio, ZW; Lei Sok, SM; Liu, PM; O U, YF; Sio Cham, ZC; Wang, JF; Wu, W; Zhou, SX	1
Ardissino, D; Armstrong, PW; Bhatt, DL; Fox, KA; Goodman, SG; Hamm, CW; Leonardi, S; Lopes, RD; Martinez, F; Neely, B; Neely, ML; Nicolau, JC; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ	1
Mancone, M; Sardella, G	1
Aggarwal, N; Angiolillo, DJ; Antoun, P; Bass, TA; Been, L; Cho, JR; Durairaj, A; Faz, GT; Franchi, F; Guzman, LA; Hu, J; Kureti, M; Park, Y; Rollini, F; Suryadevara, S; Thano, E; Zenni, MM	1
Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ	1
Ruiz-Nodar, JM	1
Broe, A; Diness, TG; Emneus, M; Gislason, GH; Green, A; Hasvold, P; Pottegård, A	1
Armstrong, PW; Boden, WE; Fox, KA; Hafley, G; Hagström, E; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Sidhu, MS; White, HD; Winters, KJ	1
Bal Dit Sollier, C; Deye, N; Dillinger, JG; Drouet, L; Henry, P; Llitjos, JF; Megarbane, B; Sideris, G; Voicu, S	1
Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S	1
Abu-Much, A; Asher, E; Atar, S; Beigel, R; Goldenberg, I; Matetzky, S; Mazin, I; Polak, A; Sabbag, A; Segev, A; Shlezinger, M; Zahger, D	1
Aonuma, K; Gosho, M; Hoshi, T; Nogami, A; Sato, A	1
Gearman, DJ; Ingimarsson, JP; Krambeck, AE; Scales, J; Sharma, V; Westerman, ME	1
Armstrong, PW; Bhatt, DL; Corbalán, R; Cyr, DD; Fox, KA; Jackson, LR; Lopes, RD; Lüscher, TF; Magnus Ohman, E; Martinez, F; Neely, ML; Piccini, JP; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ	1
Fukumoto, Y; Katsuda, Y; Katsuki, Y; Kawasaki, T; Koiwaya, H; Murasato, Y; Otsuka, Y; Sasaki, KI; Shibata, Y; Shimamatsu, J; Ueno, T; Umeji, K	1
Bolek, T; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J	1
Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M	1
Anstrom, KJ; Armstrong, PW; Boden, WE; Clapp-Channing, N; Cowper, P; Davidson-Ray, L; Fakhouri, W; Fox, KA; Gašparović, V; Hochman, JS; Kaul, P; Knight, JD; Mark, DB; McCollam, P; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD	1
Ikeda, Y; Kondo, K; Matsushima, N; Umemura, K	1
Gershlick, AH; Gunarathne, A; Hussain, S	1
Kinsara, AJ	1
Beuil, S; Chau, Y; Gaudart, J; Lonjon, M; Sachet, M; Sedat, J	1
Ardissino, D; Armstrong, PW; Bhatt, DL; Cornel, JH; Erlinge, D; Fox, KA; Gurbel, PA; Jakubowski, JA; Neely, B; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD	1
Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A	1
Bode, C; Gibson, CM; James, S; Ohman, EM; Povsic, TJ; Roe, MT; Steg, PG; Welsh, RC	1
Kinnaird, T; Kotronias, RA; Kwok, CS; Mamas, MA; Wong, CW; Zaman, A	1
Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J	1
Barbour, C; Gesheff, T	1
Colás, C; Cubero, JL; Millán, P; Simó Sánchez, B	1
Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW	1
Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M	1
Coons, JC; Iasella, CJ; Kane-Gill, SL; Verlinden, NJ	1
Eichelberger, B; Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Panzer, S; Pultar, J; Seidinger, D; Wadowski, PP	1
Arima, Y; Hokimoto, S; Ishii, M; Ito, M; Iwashita, S; Kaikita, K; Kojima, S; Mitsuse, T; Oimatsu, Y; Sueta, D; Takahashi, A; Tsujita, K; Yamamoto, E	1
Van de Werf, F	1
Baber, U; Vogel, B	1
Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW	1
Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V	1
Armstrong, PW; Bhatt, DL; Cyr, DD; Dalby, AJ; Fox, KAA; Gottlieb, S; Magnus Ohman, E; McGuire, DK; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Winters, KJ; Wiviott, SD	1
Akasaka, T; Hirata, KI; Iwasaki, M; Kinutani, H; Konishi, A; Kuroda, M; Nakamura, M; Osue, T; Otake, H; Saito, S; Shinke, T; Shite, J; Takahashi, H; Takaya, T; Terashita, D; Uzu, K	1
Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R	1
Bachelot-Loza, C; Belleville-Rolland, T; Gaussem, P; Godier, A; Helley, D; Martin, AC	1
Budaj, A; Ramotowski, B; Żuk, A	1
Anuwatworn, A; Kumar, V; Petrasko, M; Stys, A; Yee, J	1
Brugaletta, S; Campo, G; Cortese, B; Geraci, S; Ielasi, A; Ishida, K; Latib, A; Nicolini, E; Poli, A; Rapetto, C; Scotto di Uccio, F; Secco, GG; Tespili, M; Varricchio, A; Vicinelli, P	1
Athanasiou, A; Damaskos, C; Moris, D; Politou, M; Spartalis, E; Spartalis, M; Tzatzaki, E	1
Cao, PG; Guo, DD; Quan, AJ; Shang, LL; Zhao, HY	1
Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C	1
Landmesser, U; Stähli, BE	1
Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Camoin-Jau, L; Cuisset, T; Deharo, P; Fernandez, M; Fourcade, L; Ibrahim, M; Johnson, TW; Morange, PE; Quilici, J; Suchon, P; Verdier, V	1
Ahn, Y; Chae, IH; Chae, JK; Chae, SC; Cho, MC; Han, JK; Hur, SH; Jeong, MH; Kang, HJ; Kang, J; Kim, HS; Kim, YJ; Koo, BK; Park, KW; Seong, IW; Seung, KB; Yang, HM	1
Abenhaim, L; Benichou, J; Bonello, L; Cottin, Y; Dallongeville, J; Danchin, N; Delarche, N; Falissard, B; Furber, A; Ghanem, F; Grimaldi-Bensouda, L; Leclercq, F; Morel, O; Puymirat, E	1
Bath, PM; Heptinstall, S; May, J	1
Hirata, KI; Kijima, Y; Kozuki, A; Masano, T; Nagoshi, R; Otake, H; Shibata, H; Shinke, T; Shite, J; Takeshige, R; Tsukiyama, Y; Yanaka, KI	1
Brunner, S; Hamm, W; Lackermair, K; Mehr, M; Rizas, K	1
Dawood, BB; Hayes, J; Hoskins, HC; Protty, MB; Wilkins, SJ	1
Dannenberg, L; Dimitroulis, D; Golabkesh, M; Helten, C; Jung, C; Kelm, M; Knoop, B; Naguib, D; Pöhl, M; Polzin, A; Zeus, T	1
Ariyoshi, N; Fujii, K; Fujimoto, Y; Kitahara, H; Kobayashi, Y; Kohno, Y; Nishi, T; Ohno, Y	1
Ann, SH; Cho, YR; Guo, L; Kim, MH; Kim, SJ; Kim, YD; Li, J; Lomakin, N; Park, K; Park, TH; Serebruany, V; Shin, ES; Song, K	1
Niu, P; Ouyang, S; Xiao, M; Zhuo, B; Zhuo, X	1
Bermúdez, D; Galera, Á; Garcia Rinaldi, R; Quinones, J; Quinones, S; Rodriguez-Acosta, J	1
Calabria, S; Cimminiello, C; Dondi, L; Maggioni, AP; Martini, N; Pedrini, A; Ronconi, G	1
Li, J; Yan, G	1
De Rosa, R; Palmerini, T; Piscione, F	1
Barbieri, L; Carriero, A; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M	1
Cho, YR; Choi, SY; Kim, MH; Min Lee, K; Park, TH; Sung Park, J; Yun, SC	1
Fujii, T; Hayashi, T; Hirata, KI; Igarashi, N; Ishihara, T; Kadotani, M; Kawamori, H; Matsumoto, D; Matsuura, A; Nagano, Y; Nagasawa, A; Okada, M; Onishi, H; Otake, H; Sakakibara, T; Shinke, T; Shite, J; Sugizaki, Y; Takeshige, R; Toba, T; Tsukiyama, Y; Yamamoto, H; Yanaka, K; Yasaka, Y	1
Abildgaard, U; Alber, H; Conen, D; Eberli, F; Galatius, S; Gilgen, N; Hansen, KW; Jeger, RV; Kaiser, C; Kurz, DJ; Müller, C; Naber, C; Osswald, S; Pedrazzini, G; Pfisterer, M; Rickenbacher, P; Rickli, H; Vogt, DR; Vuilliomenet, A; Weilenmann, D	1
Aradi, D; Dézsi, DA; Freynhofer, MK; Geisler, T; Gross, L; Haller, PM; Hein-Rothweiler, R; Huber, K; Huczek, Z; Massberg, S; Orban, M; Sibbing, D; Toth-Gayor, GG; Trenk, D	1
Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I	1
Arashi, H; Ebihara, S; Fujii, S; Hagiwara, N; Honda, A; Jujo, K; Kawamoto, T; Mori, F; Nakao, M; Ota, Y; Otsuki, H; Saito, K; Takagi, A; Tanaka, H; Tanaka, K; Yamaguchi, J; Yoshikawa, M	1
Kozuma, K	1
Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Blanco, PF; Boccuzzi, G; Cequier, A; Cerrato, E; Cortese, M; D Ascenzo, F; De Filippo, O; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Magnani, G; Manzano-Fernández, S; Montabone, A; Montefusco, A; Morbiducci, U; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I	1
Abe, S; Inoue, T; Kanaya, T; Koyabu, Y; Nakajima, T; Obi, S; Sakuma, M; Toyoda, S; Yoneda, S	1
Goldberg, R; Gore, J; Hariri, E; Lessard, D; Rade, J	1
Cinar, C; Duzgun, F; Gok, M; Oran, I	1
Benedetto, U; Doble, B; Harris, J; Johnson, TW; Lasserson, D; Loke, Y; Mumford, A; Pithara, C; Pufulete, M; Redwood, S; Reeves, BC; Rogers, CA; Sterne, JAC; Wordsworth, S	1
Andric, T; Haller, PM; Huber, K; Jäger, B; Kahl, BS; Piackova, E; Stojkovic, S; Vargas, KG; Wojta, J	1
Carriero, A; De Luca, G; Kedhi, E; Marcolongo, M; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M	1
Abe, M; Ando, K; Doi, M; Domei, T; Furukawa, Y; Hanaoka, KI; Hata, Y; Hibi, K; Ikari, Y; Kadota, K; Kawai, K; Kimura, T; Kozuma, K; Morimoto, T; Morino, Y; Nakagawa, Y; Nakao, K; Nanasato, M; Natsuaki, M; Noda, T; Ohya, M; Okayama, H; Sakamoto, H; Seino, Y; Shiomi, H; Suematsu, N; Suwa, S; Tada, T; Takagi, K; Takamisawa, I; Tanabe, K; Toyota, T; Watanabe, H; Yagi, M; Yokomatsu, T	1
Al Sultan, AA; Almekhlafi, MA; Assis, Z; Goyal, M; Kashani, N; Podlasek, A	1
Farrokh, S; Hui, F; Lara, LR; Nault, K; Owusu, K; Spoelhof, B	1
Andric, T; Haller, PM; Huber, K; Jäger, B; Piackova, E; Spittler, A; Stojkovic, S; Wisgrill, L; Wojta, J	1
Ajisaka, H; Fukumoto, Y; Harada, A; Hirakawa, Y; Ishimatsu, T; Ishizaki, Y; Kagiyama, K; Kakuma, T; Katsuki, Y; Kawasaki, T; Murasato, Y; Sasaki, KI; Shimamatsu, J; Tashiro, H; Ueno, T; Yokoi, H	1
Amos, D; Brieger, D; Elder, A; Lowe, HC; McGhie, D	1
Iizuka, T; Kitazono, T; Kozuma, K; Nakamura, M; Nakamura, S; Sekine, T; Shiosakai, K	1
Alexopoulos, D; Ariza-Solé, A; Assi, EA; Autelli, M; Bernardi, A; Bianco, M; Blanco, PF; Boccuzzi, G; Cequier, A; Cerrato, E; D'ascenzo, F; Destefanis, P; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Gallo, D; Garay, A; Gili, S; Giustetto, C; Gravinese, C; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lopez-Cuenca, Á; Luciano, A; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Peyracchia, M; Pousa, IM; Pozzi, R; Quadri, G; Queija, BC; Raposeiras Roubin, S; Rinaldi, M; Rognoni, A; Rossini, R; Srdanovic, I; Taha, S; Templin, C; Valgimigli, M; Varbella, F; Velicki, L; Xanthopoulou, I	1
Birnbaum, Y; Chen, H; Nylander, S; Sampaio, LC; Tran, D; Ye, Y	1
Liao, YWB; Wang, TKM	1
Ajjan, RA; Barwari, T; Grant, PJ; Mayr, M; Parker, WAE; Pearson, SM; Phoenix, F; Schulte, C; Storey, RF	1
Antman, EM; Huang, S; Neely, M; Ohman, EM; Roe, MT; Sun, MT; Wallentin, L; Wiviott, SD; Wong, CX	1
Álvarez-Antón, S; Carballeira, D; Concepción, R; Dejuán-Bitriá, C; Del Castillo, H; Delgado-Calva, FA; López-Soberón, E; Marschall, A; Martí, D; Morales, MJ; Palazuelos, J; Pérez-Guzmán, J	1
Ajjan, RA; Naseem, KM; Sagar, RC	1
Bell, H; Dexter, M; Pasalic, L; Steinfort, B	1
Fukuta, H; Hagiwara, H; Ishizawa, K; Kamiya, T; Kimura, K; Niimura, T; Ohte, N; Zamami, Y	1
Abe, T; Bekki, M; Fujimoto, K; Fukumoto, Y; Harada, A; Hirakawa, Y; Honda, A; Igata, S; Kurata, S; Maeda-Ogata, S; Sugiyama, Y; Tahara, A; Tahara, N; Ueno, T	1
Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K	1
Byun, JK; Cha, J; Choi, BG; Choi, CU; Choi, JY; Choi, SY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JS; Kim, W; Na, JO; Oh, DJ; Park, CG; Park, Y; Rha, SW; Roh, SY; Seo, HS	1
Baldetti, L; Beneduce, A; Calvo, F; Capodanno, D; Cappelletti, AM; D'Ascenzo, F; De Ferrari, GM; Gallone, G; Godino, C; Gramegna, M; Melillo, F; Moroni, F; Pagnesi, M; Venuti, A	1
Gager, GM; Hengstenberg, C; Jilma, B; Kolesnik, E; Lang, IM; Prüller, F; Siller-Matula, JM; Toma, A; von Lewinski, D; Wallner, M; Winter, MP	1
Cimino, S; Cirillo, P; Coscioni, E; Esposito, G; Ferrone, M; Gargiulo, G; Giugliano, G; Ilardi, F; Morisco, C; Paolillo, R; Perrino, C; Schiattarella, GG; Stabile, E; Verde, N	1
Murphy, SA; O'Donoghue, ML; Sabatine, MS	1
Choi, YH; Deppe, AC; Gerfer, S; Liakopoulos, O; Schlachtenberger, G; Wahlers, TCW; Zeriouh, M	1
Choi, JH; Chon, MK; Chun, KJ; Hwang, KW; Jung, SM; Kim, JH; Kim, JS; Lee, SH; Lee, SY; Park, YH	1
Jhaj, R; Khandelwal, G; Najmi, A; Ray, A; Sadasivam, B	1
Bae, JW; Bong, JM; Chun, KJ; Han, JK; Hwang, D; Kang, HJ; Kang, J; Kim, HS; Koo, BK; Lee, BK; Lim, YH; Park, KW; Rhew, JY; Yang, HM	1
Campos, CM; Cavalcante, R; de Almeida Sampaio, FB; De Martino, F; Falcão, BAA; Guimarães, PO; Hara, H; Kawashima, H; Kogame, N; Leite, RS; Lemos, PA; Meireles, GC; Modolo, R; Morais, GR; Moulin, B; Ono, M; Onuma, Y; Ribeiro, EE; Serruys, PW; Tinoco, J; Wang, R	1
Angiolillo, DJ; Baber, U	1
Abe, Y; Hagimoto, H; Inoue, K; Kawakita, M; Kokubun, H; Kubota, M; Makita, N; Matsuoka, T; Murata, S; Suzuki, I; Tohi, Y; Tsutsumi, N; Yamasaki, T	1
Elkady, EF; Fouad, MA; Mohammad, MA; Salem, WA	1
Corbett, SJ; Ftouh, S; Lewis, S; Lovibond, K	1
Guimarães, PO; Kogame, N; Lemos, PA; Modolo, R; Serruys, PW	1
Agarwal, S; Agarwal, SK	1
Matoba, S; Ookura, T; Shoji, K; Yanishi, K; Zen, K	1
Cassese, S; Holdenrieder, S; Kastrati, A; Ndrepepa, G	1
Adachi, K; Hasebe, A; Hayakawa, M; Higashiguchi, S; Hirose, Y; Ishihara, T; Kawazoe, Y; Kumai, T; Matsumoto, S; Nakahara, I; Omi, T; Sadato, A; Suyama, K; Suyama, Y; Suzuki, T; Tanabe, J; Wakako, A; Watanabe, S; Yamashiro, K	1
Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S	1
Babayiğit, E; Çamlı, E; Kurt, E; Ulus, T; Verdiyev, H	1
Jneid, H; Kamran, H; Kayani, WT; Khalid, U; Levine, GN; Nambi, V; Virani, SS	1
Bae, JW; Cho, DK; Choi, SH; Gwon, HC; Hahn, JY; Jeong, JO; Oh, JH; Park, YH; Rha, SW; Song, PS; Song, YB	1
Buttà, C; Erne, P; Krüll, J; Moccetti, M; Pedrazzini, GB; Radovanovic, D; Rickli, H; Roberto, M; Tersalvi, G	1
Cassese, S; Holdenrieder, S; Joner, M; Kastrati, A; Kessler, T; Kufner, S; Laugwitz, KL; Mayer, K; Menichelli, M; Ndrepepa, G; Neumann, FJ; Richardt, G; Schunkert, H; Wiebe, J; Xhepa, E	1
Amano, T; Ikari, Y; Inohara, T; Ishii, H; Kohsaka, S; Nishida, H; Noma, S; Shimoji, K; Tanaka, N; Ueno, K; Yamaji, K; Yashima, F	1
Hayakawa, M; Hosoo, H; Hyodo, A; Ishikawa, E; Ito, Y; Marushima, A; Matsumaru, Y; Sato, M; Suzuki, K; Takigawa, T; Tsuruta, W	1
Ferro, A; Passacquale, G; Perera, D; Sharma, P	1
Alkhalil, M; Bell, A; Cantor, WJ; Goodman, SG; Kuzemczak, M; Stern, S; Welsford, M	1
Akin, I; Bernlochner, I; Cassese, S; Gewalt, S; Hemetsberger, R; Ibrahim, T; Joner, M; Kastrati, A; Kufner, S; Lahu, S; Laugwitz, KL; Mayer, K; Menichelli, M; Ndrepepa, G; Neumann, FJ; Richardt, G; Sager, HB; Schunkert, H; Schüpke, S; Valina, C; Witzenbichler, B; Wöhrle, J; Xhepa, E	1
Babiy-Pachomow, O; Bhogal, P; Cimpoca, A; Ganslandt, O; Henkes, H; Khanafer, A; Kurucz, P	1
Angelini, F; Baldetti, L; Bocchino, PP; Chieffo, A; Conrotto, F; D'Ascenzo, F; de Ferrari, GM; DE Filippo, O; DE Lio, G; Melillo, F; Montefusco, A; Omedè, P; Piroli, F; Saglietto, A	1
Amos, D; Brieger, D; Chew, DP; Hou, M; Hyun, K; Kritharides, L	1
Bagga, S; Bedekar, R; Camaj, A; Cao, D; Chandiramani, R; Claessen, B; Giustino, G; Kini, A; Koshy, AN; Kyaw, H; Levin, MA; Mehran, R; Nicolas, J; Roumeliotis, A; Sartori, S; Sharma, SK; Waseem, Z; Zhang, Z	1
Byun, JS; Choi, HH; Jang, KM; Lee, SH; Nam, TK	1
Bhatt, DL; Butt, JH; Christensen, MK; Fosbøl, EL; Gislason, G; Godtfredsen, SJ; Jørgensen, SH; Kragholm, KH; Køber, L; Leutscher, P; Pareek, M; Sessa, M; Torp-Pedersen, C	1
Harris, J; Johnson, TW; Lasserson, D; Loke, YK; Mahadevan, K; Mumford, A; Pouwels, K; Pufulete, M; Reeves, BC	1
Alexander, JH; Bhatt, DL; Budaj, A; Campo, G; Coppolecchia, R; Eikelboom, J; Ferreiro, JL; Hermanides, RS; James, SK; Jones, WS; Keller, L; Kirsch, B; Merkely, B; Mundl, H; Rao, SV; Shibasaki, T	1
Angiolillo, DJ; Been, L; Franchi, F; Galli, M; Rollini, F; Zenni, MM	1
Bernardo, E; Fernández-Ortiz, A; Gómez-Polo, JC; Jiménez, JJ; Martín-Asenjo, R; Moreno, G; Ortega-Pozzi, MA; Pérez-Villacastín, J; Vilacosta, I; Vivas, D	1
Abhaichand, R; Agrawal, DK; Arambam, P; Bangalore, S; Banker, D; Chandra, S; Garg, R; Kaul, U; Khan, A; Koduganti, SC; Mody, R; Moorthy, N; Parida, AK; Reddy, KMK; Sarma, PR; Sharma, R; Sinha, SK	1
Asano, T; Garg, S; Ishibashi, Y; Kageyama, S; Katagiri, Y; Kawashima, H; Kogame, N; Kotoku, N; Kozuma, K; Masuda, S; Miyazaki, Y; Morino, Y; Muramatsu, T; Nakamura, M; Nakatani, S; Nakazawa, G; Ninomiya, K; Okamura, T; Onuma, Y; Ozaki, Y; Serruys, PW; Takahashi, H; Takahashi, K; Tanabe, K; Tateishi, H; Tu, S	1
Appelman, Y; Boersma, E; de Vries, AG; Doevendans, PA; Smits, PC; Ten Haaf, ME; van der Linden, MMJM; van Geuns, RJ	1
Ito, Y; Kimata, M; Koseki, T; Sekido, K; Tanaka, J; Yamada, S	1
Andrade, PB; Angiolillo, DJ; Antunes, MO; Assis, SRL; Bacal, F; Bergo, RR; Berwanger, O; Costa, TAO; Dall'Orto, FTC; de Paula, JET; Franken, M; Furtado, RHM; Guimarães, PO; Hirai, JCS; Joaquim, RM; Lemos, PA; Lopes, RD; Mangione, FM; Mariani, J; Monfardini, F; Nascimento, BR; Nicolau, JC; Ohe, LN; Onuma, Y; Pitta, FG; Sampaio, FBA; Sarmento-Leite, R; Serpa, RG; Serruys, PW; Silveira, FS; Silveira, MS; Sposito, AC; Tavares, CAM; Valgimigli, M	1
Benedetto, U; Doble, B; Harris, J; Hopewell-Kelly, N; Johnson, T; Lasserson, D; Loke, Y; Mahadevan, K; Mumford, A; Pithara, C; Pouwels, KB; Pufulete, M; Redwood, S; Reeves, B; Rogers, C; Sterne, J; Wordsworth, S	1
Ahrens, I; Ako, J; Ferreiro, JL; Geisler, T; Gorog, DA; Halvorsen, S; Huber, K; Jeong, YH; Lip, GYH; Navarese, EP; Rubboli, A; Sibbing, D; Siller-Matula, JM; Storey, RF; Tan, JWC; Ten Berg, JM; Valgimigli, M; Vandenbriele, C	1
Al-Roub, NM; Almarzooq, ZI; Kinlay, S	1
Angiolillo, DJ; Cho, JY; Gorog, DA; Jang, Y; Jeong, YH; Kim, JW; Lee, SY; Yun, KH	1
Ahmad, FS; Anderson, RD; Benziger, CP; Effron, MB; Farrehi, P; Girotra, S; Gupta, K; Harrington, RA; Hernandez, AF; Jain, SK; Jones, WS; Kripalani, S; Marquis-Gravel, G; Muñoz, D; Polonsky, TS; Roe, MT; Rothman, RL; Stebbins, A; Whittle, J; Wruck, L	1
Liu, C; Ma, L	1
Cayla, G; Lattuca, B	1

Reviews

108 review(s) available for aspirin and prasugrel hydrochloride

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Seminars in thrombosis and hemostasis, 2005, Volume: 31, Issue:2 Topics: Adenosine Diphosphate; Adult; Animals; Aspirin; Biotransformation; Clinical Trials, Phase I as Topic; Clopidogrel; Collagen; Drug Evaluation, Preclinical; Drug Synergism; Fibrinolytic Agents; Hemostasis; Humans; Male; Membrane Proteins; Molecular Structure; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Thrombin; Thrombosis; Ticlopidine	2005
Aspirin and clopidogrel resistance: consideration and management. Journal of interventional cardiology, 2006, Volume: 19, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2006
Prasugrel. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:12 Topics: Adenosine Diphosphate; Animals; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Collagen; Coronary Disease; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Pyridines; Rats; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2006
Will prasugrel supersede clopidogrel for acute coronary syndromes? The Medical journal of Australia, 2008, Apr-07, Volume: 188, Issue:7 Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine	2008
Clinical profile of prasugrel, a novel thienopyridine. American heart journal, 2008, Volume: 156, Issue:2 Suppl Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes	2008
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. Journal of interventional cardiology, 2008, Volume: 21, Issue:4 Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Emergency Treatment; Evidence-Based Medicine; Fibrinolytic Agents; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Practice Guidelines as Topic; Prasugrel Hydrochloride; Recombinant Proteins; Risk Assessment; Stents; Thiophenes; Thrombosis; Ticlopidine	2008
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel? Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2008
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:12 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2008
Prasugrel development - claims and achievements. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Discovery; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2009
The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Postgraduate medicine, 2009, Volume: 121, Issue:1 Topics: Acute Coronary Syndrome; Aspirin; Humans; Life Style; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention; Thiophenes	2009
Response variability and the role of platelet function testing. The Journal of invasive cardiology, 2009, Volume: 21, Issue:4 Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
New antiplatelet drugs: beyond aspirin and clopidogrel. International journal of clinical practice, 2009, Volume: 63, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
Management of patients with high gastrointestinal risk on antiplatelet therapy. Gastroenterology clinics of North America, 2009, Volume: 38, Issue:2 Topics: Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Peptic Ulcer; Peptic Ulcer Hemorrhage; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Risk Factors; Thiophenes; Ticlopidine	2009
Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. Future cardiology, 2009, Volume: 5, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2009
Bedside evaluation of thienopyridine antiplatelet therapy. Circulation, 2009, May-19, Volume: 119, Issue:19 Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Humans; Mass Screening; Myocardial Infarction; Nephelometry and Turbidimetry; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombelastography; Ticlopidine; United States	2009
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Diabetes Complications; Drug Resistance; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2009
Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens? Fundamental & clinical pharmacology, 2009, Volume: 23, Issue:4 Topics: Animals; Aspirin; Clopidogrel; Colonic Neoplasms; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
Diabetes and acute coronary syndromes. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:3 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enoxaparin; Hirudins; Humans; Hypoglycemic Agents; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Thrombosis; Ticlopidine	2009
[Technological and biopharmaceutical aspects. Antiplatelet agents for oral administration]. Pharmazie in unserer Zeit, 2009, Volume: 38, Issue:4 Topics: Administration, Oral; Animals; Aspirin; Clopidogrel; Dipyridamole; Humans; Patents as Topic; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Challenges in oral antiplatelet therapy: ST-segment elevation myocardial infarction. The American journal of cardiology, 2009, Sep-07, Volume: 104, Issue:5 Suppl Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Dual antiplatelet therapy in coronary artery disease: a case-based approach. Cleveland Clinic journal of medicine, 2009, Volume: 76, Issue:11 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine	2009
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy. Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Thrombosis; Ticlopidine	2010
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:2 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Kidney Failure, Chronic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2010
The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine	2010
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis, 2010, Volume: 212, Issue:2 Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Glycoproteins; Humans; Models, Biological; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Thiophenes; Thromboplastin; Thrombosis; Ticlopidine	2010
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2010
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. Hospital practice (1995), 2010, Volume: 38, Issue:2 Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2010
What goes into a major acute coronary syndrome trial and what will future trials look like? Current cardiology reports, 2010, Volume: 12, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom	2010
New antithrombotic agents--insights from clinical trials. Nature reviews. Cardiology, 2010, Volume: 7, Issue:9 Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine	2010
[Antiplatelet therapy in coronary heart disease. Some problems and achivements]. Kardiologiia, 2010, Volume: 50, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration	2010
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine	2010
Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. The Annals of thoracic surgery, 2010, Volume: 90, Issue:3 Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticlopidine	2010
A comparison of the metabolism of clopidogrel and prasugrel. Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:11 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Thiophenes; Thrombosis; Ticlopidine	2010
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update. Vascular health and risk management, 2010, Oct-05, Volume: 6 Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Myocardial Revascularization; Perioperative Care; Perioperative Period; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID Circulation, 2010, Dec-14, Volume: 122, Issue:24 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticlopidine	2010
ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID The American journal of gastroenterology, 2010, Volume: 105, Issue:12 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticlopidine	2010
[New approaches and indications for the analysis of platelet function in cardiology]. Hamostaseologie, 2011, May-02, Volume: 31, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
[Novel agents in antiplatelet therapy]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine	2010
Antiplatelet therapy in the perioperative period. Acta anaesthesiologica Belgica, 2010, Volume: 61, Issue:3 Topics: Aspirin; Clopidogrel; Humans; Perioperative Period; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
[Coronary heart disease - what is of importance after coronary intervention?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:5 Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Humans; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Stents; Thiophenes; Ticagrelor; Ticlopidine	2011
Triple therapy in hospitalized patients: facts and controversies. Journal of hospital medicine, 2011, Volume: 6, Issue:9 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Hospitalization; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Warfarin	2011
Triple therapy: boon or bane for high-risk CV patients? The Journal of family practice, 2011, Volume: 60, Issue:4 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Warfarin	2011
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? Current cardiology reports, 2011, Volume: 13, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine	2011
Antiplatelet options for secondary prevention in acute coronary syndromes. Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine	2011
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. Journal of the American College of Cardiology, 2011, Nov-22, Volume: 58, Issue:22 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia	2011
Unstable angina and non-ST elevation myocardial infarction. American journal of respiratory and critical care medicine, 2012, May-01, Volume: 185, Issue:9 Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2012
Advances in antiplatelet therapy for acute coronary syndromes. Postgraduate medical journal, 2012, Volume: 88, Issue:1041 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Current antiplatelet options for NSTE-ACS patients. QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Volume: 81, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2013
Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Hospital practice (1995), 2012, Volume: 40, Issue:2 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2012
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes. Expert review of clinical pharmacology, 2012, Volume: 5, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2012
Development and clinical use of prasugrel and ticagrelor. Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Clopidogrel in coronary artery disease: update 2012. Advances in cardiology, 2012, Volume: 47 Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
[Novel agents for antithrombotic therapy in cardiology]. Orvosi hetilap, 2012, Dec-23, Volume: 153, Issue:51 Topics: Adenosine; Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2012
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes. Postgraduate medicine, 2013, Volume: 125, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. European heart journal, 2013, Volume: 34, Issue:23 Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2013
Pharmacokinetic considerations for antithrombotic therapies in stroke. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:10 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Cilostazol; Clopidogrel; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stroke; Tetrazoles; Thiophenes; Thrombin; Ticlopidine; Vitamin K	2013
Use of antiplatelet drugs in the treatment of acute coronary syndromes. Cardiovascular & hematological disorders drug targets, 2013, Volume: 13, Issue:2 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgraduate medicine, 2013, Volume: 125, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. The Canadian journal of cardiology, 2013, Volume: 29, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2013
[Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions]. Ugeskrift for laeger, 2013, Sep-09, Volume: 175, Issue:37 Topics: Adenosine; Administration, Oral; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine	2013
[Thrombocyte aggregation inhibitors: what are the risks?]. Praxis, 2013, Oct-02, Volume: 102, Issue:20 Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine	2013
Use of antiplatelet agents in patients with atherosclerotic disease. Postgraduate medicine, 2013, Volume: 125, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2013
Dual antiplatelet therapy -- management in general practice. Australian family physician, 2013, Volume: 42, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2013
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke, 2014, Volume: 45, Issue:2 Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases	2014
[Differentiated antiplatelet therapy for acute coronary syndromes]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2014
Anticoagulation and antiplatelet therapy in acute coronary syndromes. Cleveland Clinic journal of medicine, 2014, Volume: 81, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2014
Optimal aspirin dose in acute coronary syndromes: an emerging consensus. Future cardiology, 2014, Volume: 10, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thiophenes; Ticagrelor	2014
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome]. Praxis, 2014, Sep-03, Volume: 103, Issue:18 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine	2014
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy. Hospital practice (1995), 2014, Volume: 42, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2014
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? American heart journal, 2014, Volume: 168, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin	2014
Prasugrel hydrochloride for the treatment of acute coronary syndromes. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:4 Topics: Acute Coronary Syndrome; Animals; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2015
[Anticoagulant therapy in secondary prevention of coronary events]. Vnitrni lekarstvi, 2014, Volume: 60, Issue:12 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin	2014
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet (London, England), 2015, Jul-18, Volume: 386, Issue:9990 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2015
Platelets in patients with aspirin-exacerbated respiratory disease. The Journal of allergy and clinical immunology, 2015, Volume: 135, Issue:6 Topics: Animals; Aspirin; Asthma, Aspirin-Induced; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Cell Movement; Clinical Trials as Topic; Eosinophils; Gene Expression; Humans; Leukotrienes; Oxazoles; Piperazines; Platelet Activating Factor; Platelet Activation; Prasugrel Hydrochloride; Receptors, Leukotriene; Thiophenes; Thromboxane A2	2015
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose? Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:13 Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome	2015
Antiplatelet therapy in acute coronary syndromes. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:14 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2015
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. Thrombosis and haemostasis, 2015, Nov-25, Volume: 114, Issue:6 Topics: Adenosine; Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Carcinogenicity Tests; Clopidogrel; Colonic Neoplasms; Drug Therapy, Combination; Female; Humans; Lactones; Male; Mice; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Neoplastic Cells, Circulating; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Factors; Species Specificity; Ticagrelor; Ticlopidine; Time Factors	2015
Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor. Current pharmaceutical design, 2016, Volume: 22, Issue:13 Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine; Transcatheter Aortic Valve Replacement	2016
Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs. Advances in experimental medicine and biology, 2017, Volume: 906 Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Drug Interactions; Esomeprazole; Gastrointestinal Hemorrhage; Gene Expression; Humans; Hydrogen-Ion Concentration; Peptic Ulcer; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine	2017
Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:11 Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thrombosis; Ticlopidine	2016
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. American heart journal, 2016, Volume: 181 Topics: Adenosine; Antithrombins; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; History, 20th Century; History, 21st Century; History, Ancient; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticagrelor; Ticlopidine	2016
Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis. Drug safety, 2017, Volume: 40, Issue:3 Topics: Aspirin; Clopidogrel; Humans; Incidence; Neoplasms; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Thienopyridines; Ticlopidine	2017
Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals. Journal of the American Association of Nurse Practitioners, 2017, Volume: 29, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Arylsulfonates; Aspirin; Clopidogrel; Disease Management; Humans; Nurse Practitioners; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine	2017
Antiplatelet treatments: recent evidence from randomized controlled trials. Current opinion in cardiology, 2017, Volume: 32, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Atherosclerosis; Blood Platelets; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine	2017
[Antiplatelet agents and transfusion]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2017, Volume: 24, Issue:3 Topics: Adenosine; Antidotes; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine	2017
A Primer on Bleeding Risk and Management Strategies of Newer Oral Anti Platelet Agents in Cardiovascular Disease. South Dakota medicine : the journal of the South Dakota State Medical Association, 2016, Volume: 69, Issue:10 Topics: Adenosine; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine	2016
The role of prasugrel in the management of acute coronary syndromes: a systematic review. European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:20 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thrombosis; Ticlopidine	2017
Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment. Herz, 2018, Volume: 43, Issue:1 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Stents; Ticagrelor	2018
Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders. Platelets, 2018, Volume: 29, Issue:5 Topics: Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; P-Selectin; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Ticlopidine	2018
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis. BMC pharmacology & toxicology, 2018, Sep-03, Volume: 19, Issue:1 Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Humans; Observational Studies as Topic; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome	2018
Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis. Journal of neurointerventional surgery, 2020, Volume: 12, Issue:2 Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Self Expandable Metallic Stents; Ticagrelor; Treatment Outcome	2020
Neuro-Interventional Use of Oral Antiplatelets: A Survey of Neuro-Endovascular Centers in the United States and Review of the Literature. Journal of pharmacy practice, 2021, Volume: 34, Issue:2 Topics: Aspirin; Clopidogrel; Embolization, Therapeutic; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome; United States	2021
Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials. Coronary artery disease, 2020, Volume: 31, Issue:3 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Ticagrelor; Warfarin	2020
Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. The American journal of cardiology, 2020, 04-15, Volume: 125, Issue:8 Topics: Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Dual Anti-Platelet Therapy; Eye Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor	2020
Antiplatelet therapies in diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2020, Volume: 37, Issue:5 Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Primary Prevention; Secondary Prevention; Thrombosis; Ticagrelor	2020
Meta-Analysis Comparing P2Y The American journal of cardiology, 2020, 06-15, Volume: 125, Issue:12 Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor	2020
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y Circulation, 2020, 08-11, Volume: 142, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Withholding Treatment	2020
Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials. Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:3 Topics: Acute Coronary Syndrome; Aspirin; Dual Anti-Platelet Therapy; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Ticagrelor	2021
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA, 2021, Apr-20, Volume: 325, Issue:15 Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor	2021
Antiplatelet therapy in cardiovascular disease: Current status and future directions. British journal of clinical pharmacology, 2022, Volume: 88, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor	2022
A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2022, 02-14, Volume: 194, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Canada; Drug Therapy, Combination; Europe; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor	2022
Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis. Minerva cardiology and angiology, 2023, Volume: 71, Issue:5 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Ticagrelor	2023
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis. Nature reviews. Cardiology, 2023, Volume: 20, Issue:12 Topics: Acute Coronary Syndrome; Aspirin; Coronary Thrombosis; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome	2023
Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk. Current opinion in cardiology, 2023, Nov-01, Volume: 38, Issue:6 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome	2023
Comparison efficacy and safety of different antiplatelet or anticoagulation drugs in chronic coronary syndromes patients: A Bayesian network meta-analysis. Medicine, 2023, Dec-01, Volume: 102, Issue:48 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Bayes Theorem; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Network Meta-Analysis; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rivaroxaban; Ticagrelor; Treatment Outcome	2023

Trials

84 trial(s) available for aspirin and prasugrel hydrochloride

Article	Year
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. European heart journal, 2006, Volume: 27, Issue:10 Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2006
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. Journal of cardiovascular pharmacology, 2007, Volume: 49, Issue:3 Topics: Adenosine Diphosphate; Adolescent; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2007
Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine	2007
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. European heart journal, 2008, Volume: 29, Issue:1 Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2008
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thrombosis and haemostasis, 2008, Volume: 99, Issue:2 Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Reference Values; Reproducibility of Results; Thiophenes; Ticlopidine	2008
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys Journal of the American College of Cardiology, 2008, May-27, Volume: 51, Issue:21 Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine	2008
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets, 2008, Volume: 19, Issue:4 Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thrombosis and haemostasis, 2008, Volume: 100, Issue:4 Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cell Communication; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Monocytes; P-Selectin; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. Journal of pharmacokinetics and pharmacodynamics, 2008, Volume: 35, Issue:6 Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. American heart journal, 2009, Volume: 157, Issue:3 Topics: Anticoagulants; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Optical Rotation; Phosphorylation; Piperazines; Point-of-Care Systems; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2009
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665 Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. European heart journal, 2009, Volume: 30, Issue:14 Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genetic Variation; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio American heart journal, 2009, Volume: 158, Issue:3 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial. Drugs & aging, 2009, Volume: 26, Issue:9 Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aging; Aspirin; Bleeding Time; Body Mass Index; Confidence Intervals; Drug Therapy, Combination; Fasting; Female; Humans; Least-Squares Analysis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Statistics, Nonparametric; Tablets, Enteric-Coated; Thiophenes; Young Adult	2009
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary. Postgraduate medicine, 2010, Volume: 122, Issue:1 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine	2010
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC medicine, 2011, Jan-12, Volume: 9 Topics: Aspirin; Clopidogrel; Demography; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2; Risk Factors; Thiophenes; Ticlopidine	2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. European heart journal, 2011, Volume: 32, Issue:7 Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult	2011
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON- Circulation, 2011, Jun-14, Volume: 123, Issue:23 Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombolytic Therapy; Ticlopidine	2011
Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. Thrombosis research, 2012, Volume: 129, Issue:5 Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Young Adult	2012
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology, 2012, Jul-31, Volume: 60, Issue:5 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause of Death; Chest Tubes; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Retrospective Studies; Risk Adjustment; Thiophenes; Ticlopidine	2012
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. Journal of the American College of Cardiology, 2012, Jun-19, Volume: 59, Issue:25 Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epidemiologic; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2012
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. The New England journal of medicine, 2012, Oct-04, Volume: 367, Issue:14 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Ticlopidine	2012
Randomized comparison of new dual-antiplatelet therapy (aspirin, prasugrel) and triple-antiplatelet therapy (aspirin, clopidogrel, cilostazol) using P2Y12 point-of-care assay in patients with STEMI undergoing primary PCI. International journal of cardiology, 2013, Sep-20, Volume: 168, Issue:1 Topics: Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Tetrazoles; Thiophenes; Ticlopidine	2013
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA, 2012, Nov-07, Volume: 308, Issue:17 Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22 Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Retreatment; Stents; Thiophenes; Ticlopidine	2012
Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:1 Topics: Acute Coronary Syndrome; Adult; Aspirin; Biotransformation; Blood Platelets; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemostasis; Humans; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Transfusion; Prasugrel Hydrochloride; Prospective Studies; Thiophenes	2013
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm American heart journal, 2012, Volume: 164, Issue:5 Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Europe; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Ischemia; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Sample Size; Single-Blind Method; Sirolimus; Spectroscopy, Near-Infrared; Thiophenes; Tissue Scaffolds; Tomography, X-Ray Computed; Ultrasonography, Interventional	2012
The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. Journal of the American College of Cardiology, 2013, Aug-06, Volume: 62, Issue:6 Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticlopidine	2013
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation, 2013, Aug-20, Volume: 128, Issue:8 Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2013
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit Journal of the American College of Cardiology, 2014, Jan-28, Volume: 63, Issue:3 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. Thrombosis and haemostasis, 2014, Volume: 111, Issue:2 Topics: Aspirin; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Obesity; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:4 Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Point-of-Care Systems; Prasugrel Hydrochloride; Pyridines; Receptors, Purinergic P2Y12; Reproducibility of Results; ROC Curve; Sensitivity and Specificity; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:2 Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome	2013
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:7 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Japan; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors	2014
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Thrombosis research, 2014, Volume: 134, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Cytochrome P-450 CYP2C19; Female; Humans; Male; Pilot Projects; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticagrelor	2014
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. American heart journal, 2014, Volume: 167, Issue:6 Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Premedication; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome	2014
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. European journal of clinical pharmacology, 2014, Volume: 70, Issue:9 Topics: Adult; Aged; Anti-Ulcer Agents; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Interactions; Female; Humans; Lansoprazole; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2014
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine	2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23 Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Time Factors	2014
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement. Circulation, 2015, Jan-06, Volume: 131, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Incidence; Internationality; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Time Factors; Treatment Outcome	2015
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome tria Circulation, 2015, Jan-06, Volume: 131, Issue:1 Topics: Absorbable Implants; Aged; Anti-Inflammatory Agents; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Metals; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Polymers; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Sirolimus; Stents; Switzerland; Thiophenes; Treatment Outcome	2015
Impact of Intravenous Lysine Acetylsalicylate Versus Oral Aspirin on Prasugrel-Inhibited Platelets: Results of a Prospective, Randomized, Crossover Study (the ECCLIPSE Trial). Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5 Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aspirin; Blood Platelets; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Lysine; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Young Adult	2015
Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:6 Topics: Adenosine; Adult; Aged; Asian People; Aspirin; Cardiac Catheterization; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Republic of Korea; Sample Size; Thrombophilia; Thrombosis; Ticagrelor	2015
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Journal of cardiology, 2016, Volume: 68, Issue:1 Topics: Acute Coronary Syndrome; Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Genotype; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine	2016
Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. JACC. Cardiovascular interventions, 2015, Dec-21, Volume: 8, Issue:14 Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome; United States	2015
Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. Journal of the American College of Cardiology, 2016, Mar-22, Volume: 67, Issue:11 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Assessment; Survival Rate; Ticlopidine; Time Factors; Treatment Outcome	2016
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study. JACC. Cardiovascular interventions, 2016, 06-13, Volume: 9, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors; Treatment Outcome	2016
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. Heart (British Cardiac Society), 2016, 08-01, Volume: 102, Issue:15 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome	2016
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. Clinical cardiology, 2016, Volume: 39, Issue:6 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome	2016
Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest. Resuscitation, 2016, Volume: 105 Topics: Acute Coronary Syndrome; Administration, Intravenous; Administration, Oral; Adult; Aged; Aspirin; Cardiopulmonary Resuscitation; Clopidogrel; Coma; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticlopidine	2016
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Journal of cardiology, 2017, Volume: 69, Issue:4 Topics: Aspirin; Atrial Fibrillation; Blood Transfusion; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridones; Stroke; Ticlopidine	2017
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. Clinical cardiology, 2016, Volume: 39, Issue:9 Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Linear Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome	2016
Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting. Cardiovascular intervention and therapeutics, 2017, Volume: 32, Issue:4 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Prosthesis Implantation; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic; Stents; Ticlopidine	2017
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. American heart journal, 2016, Volume: 178 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors	2016
Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syn American heart journal, 2016, Volume: 178 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Health Status; Humans; Linear Models; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quality of Life; Ticlopidine	2016
Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese Subjects. Clinical pharmacology in drug development, 2017, Volume: 6, Issue:4 Topics: Adult; Area Under Curve; Aspirin; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Healthy Volunteers; Humans; Japan; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Young Adult	2017
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. American heart journal, 2016, Volume: 181 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Early Medical Intervention; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Stroke; Ticlopidine; Treatment Outcome	2016
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation, 2017, May-02, Volume: 135, Issue:18 Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Incidence; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome	2017
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC. Cardiovascular interventions, 2017, 05-08, Volume: 10, Issue:9 Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Risk Factors; Stents; Stroke; Ticlopidine; Time Factors; Treatment Outcome	2017
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. European heart journal, 2017, Nov-01, Volume: 38, Issue:41 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tablets; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2017
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. American heart journal, 2017, Volume: 188 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Myocardial Revascularization; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidine; Time Factors; Treatment Outcome	2017
Morphological and pharmacological determinants of peri-procedural myocardial infarction following elective stent implantation: Optical coherence tomography sub-analysis of the PRASFIT-Elective study. Journal of cardiology, 2017, Volume: 70, Issue:6 Topics: Aged; Aspirin; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thrombosis; Ticlopidine; Tomography, Optical Coherence	2017
Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. Journal of clinical pharmacy and therapeutics, 2018, Volume: 43, Issue:3 Topics: Adenosine; Aged; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Time Factors	2018
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study. JACC. Cardiovascular interventions, 2017, 12-26, Volume: 10, Issue:24 Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Female; France; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Ticagrelor; Time Factors; Treatment Outcome	2017
Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study. Thrombosis and haemostasis, 2019, Volume: 119, Issue:4 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Circadian Rhythm; Clopidogrel; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Time Factors	2019
Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention　- From the TWMU-AF PCI Registry. Circulation journal : official journal of the Japanese Circulation Society, 2019, 04-25, Volume: 83, Issue:5 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Registries	2019
Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Stu BMJ open, 2019, 06-04, Volume: 9, Issue:6 Topics: Acute Coronary Syndrome; Adult; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; United Kingdom	2019
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA, 2019, 06-25, Volume: 321, Issue:24 Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists	2019
Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation. Heart and vessels, 2020, Volume: 35, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Substitution; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Variants; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Time Factors; Treatment Outcome	2020
Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovascular diabetology, 2020, 01-07, Volume: 19, Issue:1 Topics: Aged; Aspirin; Biomarkers; Blood Coagulation; Clopidogrel; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrin; Humans; Male; MicroRNAs; Middle Aged; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Primary Prevention; Secondary Prevention; Thrombosis; Time Factors; Treatment Outcome	2020
Incidence of Cardiovascular Events and Safety Profile of Prasugrel in Korean Patients With Acute Coronary Syndrome. Circulation journal : official journal of the Japanese Circulation Society, 2020, 08-25, Volume: 84, Issue:9 Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Republic of Korea; Stroke; Treatment Outcome	2020
Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet (London, England), 2020, 10-10, Volume: 396, Issue:10257 Topics: Acute Coronary Syndrome; Aged; Aspirin; Dose-Response Relationship, Drug; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride	2020
Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD: The ASET Pilot Study. JACC. Cardiovascular interventions, 2020, 10-12, Volume: 13, Issue:19 Topics: Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome	2020
Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. American heart journal, 2021, Volume: 236 Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Outcome and Process Assessment, Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Adjustment; Rivaroxaban; Stroke	2021
P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials. The American journal of cardiology, 2021, 07-01, Volume: 150 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor	2021
Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial. European heart journal. Cardiovascular pharmacotherapy, 2022, Sep-29, Volume: 8, Issue:7 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor	2022
Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe Open heart, 2022, Volume: 9, Issue:2 Topics: Acute Coronary Syndrome; Adolescent; Aspirin; Clopidogrel; Cohort Studies; Dinucleoside Phosphates; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor	2022
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. Circulation, 2022, 10-18, Volume: 146, Issue:16 Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Double-Blind Method; Factor XIa; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome	2022
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease. Journal of thrombosis and thrombolysis, 2022, Volume: 54, Issue:3 Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor	2022
Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial. Journal of thrombosis and thrombolysis, 2023, Volume: 55, Issue:2 Topics: Aspirin; Blood Platelets; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome	2023
Rationale and design of the TUXEDO-2 India study: Ultra-Thin strUt Supraflex Cruz versus XiencE in a Diabetic pOpulation with multi-vessel disease-2. American heart journal, 2023, Volume: 256 Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus; Everolimus; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Stroke; Ticagrelor; Treatment Outcome	2023
P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2023, Jul-17, Volume: 19, Issue:4 Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome	2023
P2Y JACC. Cardiovascular interventions, 2023, 08-14, Volume: 16, Issue:15 Topics: Acute Coronary Syndrome; Aspirin; C-Reactive Protein; Colchicine; Humans; Percutaneous Coronary Intervention; Pilot Projects; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome	2023
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. Journal of the American Heart Association, 2023, 10-17, Volume: 12, Issue:20 Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticlopidine	2023

Other Studies

158 other study(ies) available for aspirin and prasugrel hydrochloride

Article	Year
Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. International journal of clinical practice, 2006, Volume: 60, Issue:7 Topics: Angina Pectoris; Aspirin; Chronic Disease; Coronary Stenosis; Drug Therapy, Combination; Humans; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Treatment Refusal	2006
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thrombosis and haemostasis, 2007, Volume: 98, Issue:1 Topics: Adenosine Diphosphate; Adult; Aspirin; Biomarkers; Blood Cells; Calcium; Cells, Cultured; Female; Humans; Inflammation; Kinetics; Male; Middle Aged; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombosis; Up-Regulation	2007
Intensifying platelet inhibition--navigating between Scylla and Charybdis. The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2007
Prasugrel versus clopidogrel. The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Antiplatelet therapy in acute coronary syndromes. Current cardiology reports, 2008, Volume: 10, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2008
Intensive antiplatelet therapy for reduction of ischaemic events. Lancet (London, England), 2008, Aug-16, Volume: 372, Issue:9638 Topics: Aspirin; Dose-Response Relationship, Drug; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis	2008
Another view on prasugrel. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2009
Facts and controversies of aspirin and clopidogrel therapy. American heart journal, 2009, Volume: 157, Issue:3 Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine	2009
Prasugrel STEMI subgroup analysis. Lancet (London, England), 2009, May-30, Volume: 373, Issue:9678 Topics: Aspirin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Thiophenes; Ticlopidine	2009
Can we override clopidogrel resistance? Circulation, 2009, Jun-02, Volume: 119, Issue:21 Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Restenosis; Drug Resistance; Genotype; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Prodrugs; Radiography; Stents; Thiophenes; Ticlopidine	2009
[Pharmazie in unserer Zeit 4/2009]. Pharmazie in unserer Zeit, 2009, Volume: 38, Issue:4 Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticlopidine	2009
Test before you stop. Archives of surgery (Chicago, Ill. : 1960), 2009, Volume: 144, Issue:8 Topics: Adenosine; Algorithms; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2009
Weighing benefits and risks--the FDA's review of prasugrel. The New England journal of medicine, 2009, Sep-03, Volume: 361, Issue:10 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Causality; Clinical Trials as Topic; Combined Modality Therapy; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; United States; United States Food and Drug Administration	2009
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire international, 2009, Volume: 18, Issue:103 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2009
P2Y12 inhibitors: thienopyridines and direct oral inhibitors. Hamostaseologie, 2009, Volume: 29, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor	2009
Trial watch. DAPT study. Harvard heart letter : from Harvard Medical School, 2010, Volume: 20, Issue:5 Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
Response to antiplatelet treatment: from genes to outcome. Lancet (London, England), 2010, Oct-16, Volume: 376, Issue:9749 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine	2010
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Hospital practice (1995), 2010, Volume: 38, Issue:4 Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2010
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy. American heart journal, 2010, Volume: 160, Issue:6 Suppl Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Safety; Secondary Prevention; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin	2010
Resistance to anti-platelet agents. Thrombosis research, 2011, Volume: 127 Suppl 3 Topics: Adenosine; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
[Multiple arterial thrombosis and resistance to conventional antiaggregation]. Revista espanola de cardiologia, 2011, Volume: 64, Issue:9 Topics: Aged; Angiography; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Electrocardiography; Female; Femoral Artery; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2011
Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:10 Topics: Adolescent; Adult; Aspirin; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboxanes	2011
Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel. Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:10 Topics: Adenosine; Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor	2011
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome. Hospital practice (1995), 2011, Volume: 39, Issue:3 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Costs and Cost Analysis; Diagnostic Techniques and Procedures; Drug Therapy, Combination; Dyspnea; Emergency Service, Hospital; Female; Humans; Insurance Claim Review; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2011
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)? The Medical letter on drugs and therapeutics, 2011, Sep-05, Volume: 53, Issue:1372 Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Approval; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; United States	2011
A case of acute stent thrombosis during treatment with the thrombopoietin receptor agonist peptide--romiplostim. Heart, lung & circulation, 2012, Volume: 21, Issue:3 Topics: Acute Disease; Aspirin; Chest Pain; Clopidogrel; Eptifibatide; Female; Humans; Middle Aged; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Purpura, Thrombocytopenic, Idiopathic; Receptors, Thrombopoietin; Risk Factors; Stents; Thiophenes; Thrombosis; Ticlopidine; Ultrasonography, Interventional	2012
Esophageal mucosal lesion with low-dose aspirin and prasugrel mimics malignancy: a case report. World journal of gastroenterology, 2011, Sep-21, Volume: 17, Issue:35 Topics: Aspirin; Diagnosis, Differential; Drug-Eluting Stents; Esophageal Neoplasms; Esophagus; Humans; Intestinal Mucosa; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes	2011
Cost-effectiveness of prasugrel in a US managed care population. Journal of medical economics, 2012, Volume: 15, Issue:1 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cost Control; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Humans; Interviews as Topic; Male; Managed Care Programs; Middle Aged; Models, Economic; Outcome Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; United States	2012
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity. Cardiology journal, 2011, Volume: 18, Issue:6 Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Metals; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prosthesis Design; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2011
New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment. Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:4 Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Thiophenes; Ticlopidine	2012
Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. Thrombosis and haemostasis, 2012, Volume: 107, Issue:6 Topics: Animals; Anti-Inflammatory Agents; Aspirin; Biomarkers; Blood Platelets; Disease Models, Animal; Down-Regulation; Humans; Inflammation Mediators; Leukocytes; Macrophage-1 Antigen; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Piperazines; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Selenoprotein P; Shock, Septic; Thiophenes; Thromboxane B2; Tumor Necrosis Factor-alpha	2012
CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance. Connecticut medicine, 2012, Volume: 76, Issue:5 Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Resistance; Genotype; Humans; Male; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2012
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. The American journal of medicine, 2012, Volume: 125, Issue:9 Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin	2012
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia]. Der Anaesthesist, 2012, Volume: 61, Issue:8 Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive System Surgical Procedures; Drug Interactions; Hemorrhage; Humans; Male; Middle Aged; Pain, Postoperative; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine	2012
Abciximab for distal thromboaspiration catheter-related embolization in ST-segment elevated myocardial infarction. Archives of cardiovascular diseases, 2012, Volume: 105, Issue:11 Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Electrocardiography; Embolism; Enoxaparin; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Injections, Intra-Arterial; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Stents; Suction; Thiophenes; Thrombectomy	2012
Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. The American journal of cardiology, 2013, Mar-15, Volume: 111, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Chi-Square Distribution; Clopidogrel; Endpoint Determination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Statistics, Nonparametric; Thiophenes; Ticlopidine; Treatment Outcome	2013
Circulating microRNAs as novel biomarkers for platelet activation. Circulation research, 2013, Feb-15, Volume: 112, Issue:4 Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Blood Specimen Collection; Carotid Artery Diseases; Case-Control Studies; Clinical Trials as Topic; Confounding Factors, Epidemiologic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Gene Expression Profiling; Humans; Male; MicroRNAs; Piperazines; Plasma; Platelet Activation; Platelet Aggregation Inhibitors; Platelet-Rich Plasma; Prasugrel Hydrochloride; Real-Time Polymerase Chain Reaction; Serum; Thiophenes; Young Adult	2013
Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel. Cardiology, 2013, Volume: 124, Issue:2 Topics: Aged; Aspirin; Brain Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Clopidogrel; Colonic Neoplasms; Coronary Stenosis; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; Drug Therapy, Combination; Drug-Eluting Stents; Fatal Outcome; Female; Humans; Lung Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine; Time Factors	2013
Triple antithrombotic therapy with prasugrel in the stented patient: concern for more bleeding. Journal of the American College of Cardiology, 2013, May-21, Volume: 61, Issue:20 Topics: Anticoagulants; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Myocardial Ischemia; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes	2013
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. Journal of the American College of Cardiology, 2013, May-21, Volume: 61, Issue:20 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Vitamin K	2013
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:4 Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2013
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology, 2013, Volume: 124, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. European journal of clinical investigation, 2013, Volume: 43, Issue:7 Topics: Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Female; Humans; Integrin beta3; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoprotein IIb; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombin; Ticlopidine	2013
Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness. Thrombosis and haemostasis, 2013, Volume: 110, Issue:1 Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Biomarkers, Pharmacological; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2013
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. Cardiology, 2013, Volume: 126, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2013
Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation. Thrombosis and haemostasis, 2013, Volume: 110, Issue:4 Topics: Adenosine Diphosphate; Aged; Aspirin; Cell Adhesion Molecules; Coronary Artery Disease; Drug Dosage Calculations; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Pilot Projects; Piperazines; Platelet Activation; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes	2013
Critical illness-related corticosteroid insufficiency in cardiogenic shock. British journal of anaesthesia, 2013, Volume: 111, Issue:3 Topics: Adrenal Insufficiency; Adrenergic alpha-Agonists; Adult; Anti-Inflammatory Agents; Antihypertensive Agents; Aspirin; Bisoprolol; Critical Illness; Epinephrine; Fibrinolytic Agents; Hirudins; Humans; Hydrocortisone; Male; Peptide Fragments; Piperazines; Prasugrel Hydrochloride; Ramipril; Recombinant Proteins; Shock, Cardiogenic; Thiophenes; Treatment Outcome	2013
Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy. Journal of cardiovascular translational research, 2014, Volume: 7, Issue:1 Topics: Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prothrombin; Receptor, PAR-1; Thiophenes; Thrombin; Ticlopidine	2014
Acute dysphagia after myocardial infarction: an unusual complication of anticoagulation therapy. Kardiologia polska, 2014, Volume: 72, Issue:1 Topics: Anticoagulants; Aspirin; Cysts; Deglutition Disorders; Electrocardiography; Fibrinolytic Agents; Hematoma; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Premedication; Stents; Tenecteplase; Thiophenes; Thyroid Diseases; Thyroidectomy; Tissue Plasminogen Activator	2014
Smoking status and the effects of antiplatelet drugs. BMJ (Clinical research ed.), 2013, Oct-01, Volume: 347 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis. The American journal of emergency medicine, 2014, Volume: 32, Issue:5 Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Angiography; Diabetes Mellitus, Type 2; Drug Resistance; Electrocardiography; Heparin; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis; Ticlopidine	2014
Safer heart-attack prevention for seniors with revised drug regimen. Half the normal dose of prasugrel, a lifesaving medication, is just as effective as the larger dose, and reduces risk of serious side effects. DukeMedicine healthnews, 2013, Volume: 19, Issue:11 Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Secondary Prevention; Thiophenes; Ticlopidine	2013
Use of thromboelastography to tailor dual-antiplatelet therapy in patients undergoing treatment of intracranial aneurysms with the Pipeline embolization device. Journal of neurointerventional surgery, 2015, Volume: 7, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug Therapy, Combination; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thrombelastography; Ticlopidine; Treatment Outcome	2015
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. European heart journal, 2014, Jun-14, Volume: 35, Issue:23 Topics: Adenosine; Aspirin; Blood Platelets; Clopidogrel; Consensus; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
Triple antithrombotic therapy: risky but sometimes necessary. Revista espanola de cardiologia (English ed.), 2014, Volume: 67, Issue:3 Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Vitamin K	2014
Fatal bleedings with prasugrel as part of triple antithrombotic therapy. Revista espanola de cardiologia (English ed.), 2014, Volume: 67, Issue:3 Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Arteriovenous Malformations; Aspirin; Drug Therapy, Combination; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Thrombosis; Warfarin	2014
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. Journal of thrombosis and thrombolysis, 2015, Volume: 39, Issue:4 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Sex Factors; Thrombosis; Ticlopidine	2015
Dental extractions and risk of bleeding in patients taking single and dual antiplatelet treatment. The British journal of oral & maxillofacial surgery, 2015, Volume: 53, Issue:1 Topics: Absorbable Implants; Aged; Aspirin; Clopidogrel; Collagen; Ecchymosis; Female; Hematoma; Hemostasis, Surgical; Hemostatic Techniques; Humans; Male; Middle Aged; Oral Hemorrhage; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Prospective Studies; Risk Factors; Surgical Sponges; Suture Techniques; Ticlopidine; Time Factors; Tooth Extraction	2015
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ open, 2014, Oct-31, Volume: 4, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine	2014
Dual antiplatelet therapy after drug-eluting stents--how long to treat? The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23 Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine	2014
Long-term secondary prevention after high-risk stenting: a good drug for a bad stent. Circulation, 2015, Jan-06, Volume: 131, Issue:1 Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes	2015
Endobronchial biopsies on aspirin and prasugrel. Heart, lung & circulation, 2015, Volume: 24, Issue:6 Topics: Angioplasty, Balloon, Coronary; Aspirin; Biopsy, Needle; Bronchoscopy; Carcinoma, Squamous Cell; Coronary Restenosis; Coronary Stenosis; Drug-Eluting Stents; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Recurrence, Local; Patient Safety; Platelet Aggregation Inhibitors; Pneumonectomy; Prasugrel Hydrochloride; Radiography; Risk Assessment; Treatment Outcome	2015
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:3 Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Prosthesis Design; Registries; Risk Factors; Sirolimus; Ticlopidine; Time Factors; Treatment Outcome	2015
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy. The American journal of cardiology, 2015, May-01, Volume: 115, Issue:9 Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine	2015
Characterization of platelet aggregation responses in microminipigs: Comparison with miniature pigs and the influence of dual antiplatelet administration of aspirin plus prasugrel. Thrombosis research, 2015, Volume: 135, Issue:5 Topics: Administration, Oral; Animals; Aspirin; Blood Platelets; Drug Therapy, Combination; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Swine; Swine, Miniature	2015
Redesigning TRACER trial after TRITON. International journal of cardiology, 2015, Oct-15, Volume: 197 Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Hemorrhage; Humans; Lactones; Neoplasms; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Ticlopidine	2015
Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy. Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:10 Topics: Aspirin; Blood Platelets; Drug Therapy, Combination; Flow Cytometry; Humans; In Vitro Techniques; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Sensitivity and Specificity; Thromboxanes	2015
Effects of prasugrel pretreatment on angiographic myocardial perfusion parameters in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Coronary artery disease, 2015, Volume: 26, Issue:8 Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Premedication; Ticlopidine; Treatment Outcome	2015
Inhibited and Uninhibited Platelet Deposition Within a Thrombus: Does It Depend on the Antiplatelet Drug? Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:10 Topics: Aspirin; Blood Platelets; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride	2015
Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder. Texas Heart Institute journal, 2015, Volume: 42, Issue:5 Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prosthesis Design; Recurrence; Ticlopidine; Time Factors; Treatment Outcome	2015
Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study). Archives of cardiovascular diseases, 2016, Volume: 109, Issue:1 Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Registries; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome	2016
P2Y12 receptor blockade synergizes strongly with nitric oxide and prostacyclin to inhibit platelet activation. British journal of clinical pharmacology, 2016, Volume: 81, Issue:4 Topics: Adolescent; Adult; Aspirin; Blood Platelets; Drug Synergism; Epoprostenol; Healthy Volunteers; Humans; In Vitro Techniques; Male; Nitric Oxide; Nitric Oxide Donors; Platelet Activation; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Young Adult	2016
Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y12 inhibitors really more effective than clopidogrel? Resuscitation, 2016, Volume: 98 Topics: Adenosine; Aspirin; Clopidogrel; Coma; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Risk Factors; Stents; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Synergistic effect of anti-platelet and anti-inflammation of drug-coated Co-Cr substrates for prevention of initial in-stent restenosis. Colloids and surfaces. B, Biointerfaces, 2016, Apr-01, Volume: 140 Topics: Anti-Inflammatory Agents; Aspirin; Cells, Cultured; Chromium Alloys; Cobalt; Coronary Restenosis; Drug Liberation; Drug Synergism; Drug-Eluting Stents; Humans; Microscopy, Electron, Scanning; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Polyesters; Prasugrel Hydrochloride; Propolis; Sirolimus	2016
[Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention]. Zhonghua xin xue guan bing za zhi, 2016, Volume: 44, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor; Ticlopidine	2016
Save the Unlucky Unrevascularized Acute Coronary Syndrome Patient. Journal of the American College of Cardiology, 2016, Mar-22, Volume: 67, Issue:11 Topics: Acute Coronary Syndrome; Aspirin; Electrocardiography; Female; Humans; Male; Myocardial Infarction; Prasugrel Hydrochloride; Risk Assessment; Ticlopidine	2016
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit. Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors	2016
Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study. BMJ open, 2016, 05-12, Volume: 6, Issue:5 Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Denmark; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine	2016
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. Thrombosis research, 2016, Volume: 144 Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Survival Analysis; Ticagrelor; Ticlopidine	2016
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2). PloS one, 2016, Volume: 11, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Israel; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Stents; Stroke; Survival Analysis; Thrombosis; Ticagrelor; Ticlopidine	2016
The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy. Journal of endourology, 2016, Volume: 30, Issue:10 Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk; Ticagrelor; Ticlopidine; Ureteroscopy	2016
The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. Journal of diabetes research, 2016, Volume: 2016 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticlopidine	2016
SNAAP to Replace MONA. The American journal of cardiology, 2017, 08-01, Volume: 120, Issue:3 Topics: Acute Coronary Syndrome; Advanced Cardiac Life Support; American Heart Association; Anticoagulants; Aspirin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitroglycerin; Oxygen Inhalation Therapy; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; United States; Vasodilator Agents	2017
Prasugrel versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms. Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2017, Volume: 23, Issue:1 Topics: Adult; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Stents; Ticlopidine; Treatment Outcome	2017
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American Heart Association, 2016, 11-04, Volume: 5, Issue:11 Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Proportional Hazards Models; Randomized Controlled Trials as Topic; Ticlopidine	2016
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. European heart journal, 2017, Jun-01, Volume: 38, Issue:21 Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Ticagrelor; Ticlopidine	2017
Aspirin desensitization in patients with coronary artery disease: Cost savings. Medicina intensiva, 2017, Volume: 41, Issue:7 Topics: Aspirin; Clopidogrel; Coronary Disease; Cost Savings; Desensitization, Immunologic; Drug Hypersensitivity; Drug Substitution; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Salicylates; Ticlopidine	2017
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. International journal of cardiology, 2017, May-15, Volume: 235 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination; Female; Hospitalization; Humans; Incidence; Male; Medication Therapy Management; Patient Discharge; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Survival Analysis; Ticagrelor; Ticlopidine	2017
Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel. Journal of cardiovascular pharmacology and therapeutics, 2017, Volume: 22, Issue:6 Topics: Adenosine; Aged; Aspirin; Cohort Studies; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Warfarin	2017
Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy. Journal of cardiovascular translational research, 2017, Volume: 10, Issue:4 Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Reproducibility of Results; Signal Transduction; Stents; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Total Thrombus-formation Analysis System Predicts Periprocedural Bleeding Events in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, Apr-24, Volume: 6, Issue:4 Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Artery Disease; Female; Hemorrhage; Humans; Intraoperative Complications; Male; Microchip Analytical Procedures; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Risk Assessment; Ticlopidine	2017
Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy? Circulation, 2017, 05-02, Volume: 135, Issue:18 Topics: Aspirin; Belgium; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Treatment Outcome	2017
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. PloS one, 2017, Volume: 12, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prescription Drugs; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine	2017
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor. Kardiologia polska, 2017, Volume: 75, Issue:6 Topics: Adenosine; Aspirin; Clopidogrel; Coronary Vessels; Drug Hypersensitivity; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Stents; Thrombosis; Ticagrelor; Ticlopidine	2017
A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study. JACC. Cardiovascular interventions, 2017, 09-25, Volume: 10, Issue:18 Topics: Absorbable Implants; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Prosthesis Design; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome	2017
Decreased platelet inhibition by P2Y12 receptor blockers in anaemia. European journal of clinical investigation, 2018, Volume: 48, Issue:1 Topics: Adenosine; Adenosine Diphosphate; Aged; Anemia; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine	2018
Third-Generation P2Y12 Inhibitors in East Asian Acute Myocardial Infarction Patients: A Nationwide Prospective Multicentre Study. Thrombosis and haemostasis, 2018, Volume: 118, Issue:3 Topics: Aged; Asia; Aspirin; Clopidogrel; Drug Administration Schedule; Female; Humans; Incidence; Inpatients; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Republic of Korea; Stroke; Ticagrelor; Treatment Outcome	2018
Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction. Heart (British Cardiac Society), 2018, Volume: 104, Issue:19 Topics: Age Factors; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combination; Female; France; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Registries; Risk Factors; Secondary Prevention; Sex Factors; Ticagrelor	2018
Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. Journal of cardiology, 2018, Volume: 72, Issue:5 Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Prospective Studies; Registries; Stents; Thrombosis; Tomography, Optical Coherence; Treatment Outcome	2018
Effect of Physical Exercise on Platelet Reactivity in Patients with Dual Antiplatelet Therapy. International journal of sports medicine, 2018, Volume: 39, Issue:8 Topics: Adenosine Diphosphate; Aspirin; Chromogranin A; Clopidogrel; Coronary Artery Disease; Electrocardiography; Exercise; Exercise Tolerance; Humans; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thrombosis; Ticlopidine	2018
Prescribing patterns of oral antiplatelets in Wales: evolving trends from 2005 to 2016. Future cardiology, 2018, Volume: 14, Issue:4 Topics: Administration, Oral; Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor; Wales	2018
Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction. Journal of cardiovascular pharmacology, 2018, Volume: 72, Issue:4 Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Registries; Risk Factors; ST Elevation Myocardial Infarction; Stroke; Ticagrelor; Time Factors; Treatment Outcome	2018
High residual platelet reactivity after switching from clopidogrel to low-dose prasugrel in Japanese patients with end-stage renal disease on hemodialysis. Journal of cardiology, 2019, Volume: 73, Issue:1 Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Humans; Japan; Kidney Failure, Chronic; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Renal Dialysis	2019
Impact of CYP2C19 Polymorphism on Antiplatelet Potency of Prasugrel 5 and 10 mg Daily Maintenance. Cardiology, 2018, Volume: 140, Issue:3 Topics: Aged; Aspirin; Cytochrome P-450 CYP2C19; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Prospective Studies; Republic of Korea	2018
Antiplatelet Therapy for Long-Term Management of Patients with Mechanical Aortic Prostheses. The Journal of heart valve disease, 2017, Volume: 26, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aortic Valve; Aspirin; Clopidogrel; Female; Follow-Up Studies; Heart Valve Prosthesis; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Puerto Rico; Stroke; Young Adult	2017
The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects. European heart journal. Acute cardiovascular care, 2019, Volume: 8, Issue:6 Topics: Acute Coronary Syndrome; Aftercare; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Female; Health Care Costs; Hospitalization; Humans; Italy; Male; Medication Adherence; Middle Aged; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor	2019
How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing? International journal of cardiology, 2018, 11-15, Volume: 271 Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Ticlopidine	2018
Response to Letter of Li et al.: How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing? International journal of cardiology, 2018, 11-15, Volume: 271 Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Drug Therapy, Combination; Humans; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Ticlopidine	2018
Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation. Journal of cardiology, 2019, Volume: 73, Issue:3 Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Period; Prasugrel Hydrochloride; Prevalence; Stents	2019
Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy. Circulation. Cardiovascular interventions, 2018, Volume: 11, Issue:12 Topics: Aged; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Treatment Outcome	2018
Impact of dual antiplatelet therapy with adjusted-dose prasugrel on mid-term vascular response in patients undergoing elective percutaneous coronary intervention with everolimus-eluting stents. Heart and vessels, 2019, Volume: 34, Issue:6 Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Everolimus; Female; Humans; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Postoperative Complications; Prasugrel Hydrochloride; Prospective Studies; Thrombosis; Ticlopidine; Tomography, Optical Coherence	2019
Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. PloS one, 2019, Volume: 14, Issue:1 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stents; Thrombosis	2019
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. European journal of preventive cardiology, 2020, Volume: 27, Issue:7 Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Europe; Female; Hemorrhage; Humans; Male; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Registries; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Stents; Ticagrelor; Time Factors; Treatment Outcome	2020
A Main Performer May Come for Percutaneous Coronary Intervention With Atrial Fibrillation in Japanese Patients. Circulation journal : official journal of the Japanese Circulation Society, 2019, 04-25, Volume: 83, Issue:5 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Humans; Japan; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Registries	2019
Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019, Volume: 19, Issue:4 Topics: Acute Coronary Syndrome; Aged; Aspirin; Europe; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Registries; Retrospective Studies; Ticagrelor; Treatment Outcome	2019
Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention. Internal medicine (Tokyo, Japan), 2019, Aug-15, Volume: 58, Issue:16 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Ticlopidine	2019
Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction? Cardiovascular revascularization medicine : including molecular interventions, 2020, Volume: 21, Issue:2 Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Prescriptions; Drug Utilization; Dual Anti-Platelet Therapy; Female; Healthcare Disparities; Hospitalization; Humans; Male; Massachusetts; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2020
Aggregometry Response to Half-dose Prasugrel in Flow-diverting Stent Implantation. Clinical neuroradiology, 2020, Volume: 30, Issue:3 Topics: Aspirin; Cerebral Angiography; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Stents	2020
Course of platelet miRNAs after cessation of P2Y12 antagonists. European journal of clinical investigation, 2019, Volume: 49, Issue:8 Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; MicroRNAs; Middle Aged; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor	2019
Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Vascular pharmacology, 2019, Volume: 120 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Vitamin D; Vitamin D Deficiency	2019
The association of P2Y Platelets, 2020, May-18, Volume: 31, Issue:4 Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Extracellular Vesicles; Female; Humans; Male; MicroRNAs; Middle Aged; Phosphatidylserines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor	2020
Life after abciximab; what's next for intracoronary thrombus? Journal of thrombosis and thrombolysis, 2020, Volume: 49, Issue:1 Topics: Abciximab; Aged; Aspirin; Coronary Thrombosis; Heparin; Humans; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban	2020
Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II)　- 1-Year Follow-up Results of a Postmarketing Observational Study. Circulation journal : official journal of the Japanese Circulation Society, 2019, 12-25, Volume: 84, Issue:1 Topics: Aged; Aged, 80 and over; Anemia; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Japan; Male; Myocardial Ischemia; Peptic Ulcer; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Prospective Studies; Risk Factors; Thrombolytic Therapy	2019
Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. International journal of cardiology, 2020, 02-15, Volume: 301 Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Reproducibility of Results; Retrospective Studies; Risk Assessment; Ticagrelor; Treatment Outcome	2020
Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2019, Volume: 53, Issue:6 Topics: Animals; Apoptosis; Aspirin; Atrial Natriuretic Factor; Disease Models, Animal; Drug Therapy, Combination; Endoglin; Fibrosis; Gene Expression Regulation; Myocardial Infarction; Myocardial Reperfusion Injury; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proto-Oncogene Proteins c-kit; Rats; Rats, Sprague-Dawley; Stem Cells; Ticagrelor; Ventricular Function, Left; Ventricular Remodeling	2019
Impact of Anemia on the Risk of Bleeding Following Percutaneous Coronary Interventions in Patients ≥75 Years of Age. The American journal of cardiology, 2020, 04-15, Volume: 125, Issue:8 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Angina, Unstable; Anticoagulants; Antithrombins; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Artery Disease; Drug-Eluting Stents; Female; Gastrointestinal Hemorrhage; Hemorrhage; Heparin; Hirudins; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Stents; Ticagrelor; Urologic Diseases	2020
Failure of platelet function analyser 200 to demonstrate clinical clopidogrel resistance in a patient undergoing intracranial vascular stenting. BMJ case reports, 2020, Mar-12, Volume: 13, Issue:3 Topics: Aged; Aspirin; Clopidogrel; Diagnosis, Differential; Drug Resistance; Humans; Intracranial Aneurysm; Ischemic Attack, Transient; Magnetic Resonance Imaging; Male; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Preoperative Care; Stents; Stroke; Thromboembolism; Treatment Outcome; Withholding Treatment	2020
Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases. International journal of medical sciences, 2020, Volume: 17, Issue:6 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists	2020
Switching from clopidogrel to prasugrel resolves vascular inflammation in patients receiving long-term aspirin plus clopidogrel therapy after coronary stent implantation. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2021, Volume: 28, Issue:3 Topics: Aged; Aspirin; Clopidogrel; Female; Fluorodeoxyglucose F18; Humans; Male; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Positron Emission Tomography Computed Tomography; Prasugrel Hydrochloride; Radiopharmaceuticals; Stents	2021
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. JAMA network open, 2020, 04-01, Volume: 3, Issue:4 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Death; Drug Therapy, Combination; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Renal Insufficiency, Chronic; Retrospective Studies; Risk Assessment; Stroke	2020
Cilostazol-based triple versus potent P2Y12 inhibitor-based dual antiplatelet therapy in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart and vessels, 2020, Volume: 35, Issue:9 Topics: Aged; Asian People; Aspirin; Cilostazol; Clopidogrel; Databases, Factual; Dual Anti-Platelet Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome	2020
Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. European journal of clinical investigation, 2020, Volume: 50, Issue:11 Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Cardiovascular Diseases; Clopidogrel; Dual Anti-Platelet Therapy; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prognosis; Proportional Hazards Models; Prospective Studies; Secondary Prevention; Stroke; Survival Rate; Ticagrelor	2020
Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome. Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:9 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Resistance; Dual Anti-Platelet Therapy; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor; Treatment Outcome	2020
Major Bleeding after Surgical Revascularization with Dual Antiplatelet Therapy. The Thoracic and cardiovascular surgeon, 2020, Volume: 68, Issue:8 Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Databases, Factual; Dual Anti-Platelet Therapy; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Reoperation; Retrospective Studies; Risk Assessment; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome	2020
Duration of Dual Antiplatelet Therapy After PCI: How Short Can We Go? JACC. Cardiovascular interventions, 2020, 10-12, Volume: 13, Issue:19 Topics: Aspirin; Coronary Vessels; Humans; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome	2020
Effect of Continued Perioperative Anticoagulant Therapy on Bleeding Outcomes Following Robot-assisted Radical Prostatectomy. Urology, 2021, Volume: 148 Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Blood Transfusion; Clopidogrel; Continuity of Patient Care; Humans; Incidence; Male; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Robotic Surgical Procedures; Thrombosis; Warfarin	2021
Analysis of Aspirin, Prasugrel and Clopidogrel in Counterfeit Pharmaceutical and Herbal Products: Plackett-Burman Screening and Box-Behnken Optimization. Journal of chromatographic science, 2021, Aug-18, Volume: 59, Issue:8 Topics: Aspirin; Chromatography, High Pressure Liquid; Clopidogrel; Humans; Pharmaceutical Preparations; Prasugrel Hydrochloride	2021
Acute coronary syndromes: summary of updated NICE guidance. BMJ (Clinical research ed.), 2021, 01-15, Volume: 372 Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Cardiac Rehabilitation; Clopidogrel; Combined Modality Therapy; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Secondary Prevention; ST Elevation Myocardial Infarction; Ticagrelor; United Kingdom	2021
Reply: Elimination of Aspirin From PCI Pharmacotherapy. JACC. Cardiovascular interventions, 2021, 01-25, Volume: 14, Issue:2 Topics: Aspirin; Coronary Vessels; Humans; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome	2021
Elimination of Aspirin From PCI Pharmacotherapy. JACC. Cardiovascular interventions, 2021, 01-25, Volume: 14, Issue:2 Topics: Aspirin; Coronary Vessels; Humans; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome	2021
Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report. BMC cardiovascular disorders, 2021, 01-30, Volume: 21, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Aspirin; Colorectal Neoplasms; Coronary Artery Disease; Coronary Thrombosis; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Fatal Outcome; Fibrinolytic Agents; Humans; Male; Percutaneous Coronary Intervention; Phenylurea Compounds; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridines; Pyridones; Risk Factors; Stents; Treatment Outcome; Venous Thrombosis	2021
Creatine kinase and bleeding in patients with acute coronary syndromes. European journal of clinical investigation, 2021, Volume: 51, Issue:7 Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Creatine Kinase; Dual Anti-Platelet Therapy; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor	2021
Reduction of thromboembolic complications during the endovascular treatment of unruptured aneurysms by employing a tailored dual antiplatelet regimen using aspirin and prasugrel. Journal of neurointerventional surgery, 2021, Volume: 13, Issue:11 Topics: Aspirin; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies	2021
How to manage aspirin hypersensitivity in a patient with ST-segment elevation myocardial infarction and a drug-eluting stent. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2021, Volume: 49, Issue:2 Topics: Aged; Aspirin; Desensitization, Immunologic; Drug Administration Schedule; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Humans; Immunosuppressive Agents; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction	2021
Dual antiplatelet therapy is under-prescribed in patients with surgically treated acute myocardial infarction. Interactive cardiovascular and thoracic surgery, 2021, 10-29, Volume: 33, Issue:5 Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Treatment Outcome	2021
Prognostic value of haemoglobin drop in patients with acute coronary syndromes. European journal of clinical investigation, 2021, Volume: 51, Issue:12 Topics: Acute Coronary Syndrome; Aged; Aspirin; Dual Anti-Platelet Therapy; Female; Hemoglobins; Humans; Male; Middle Aged; Mortality; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prasugrel Hydrochloride; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Ticagrelor	2021
In-hospital Bleeding Outcomes of Oral Anticoagulant and Dual Antiplatelet Therapy During Percutaneous Coronary Intervention: An Analysis From the Japanese Nationwide Registry. Journal of cardiovascular pharmacology, 2021, 04-01, Volume: 78, Issue:2 Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Dual Anti-Platelet Therapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Japan; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Registries; Retrospective Studies; Warfarin	2021
Antiplatelet Therapy and Periprocedural Risk Factor Analysis for Pipeline Embolization Device Treatment of Unruptured Internal Carotid Artery Aneurysms: A Retrospective, Multicenter Analysis. World neurosurgery, 2022, Volume: 157 Topics: Adult; Aged; Aspirin; Carotid Artery, Internal; Clopidogrel; Dual Anti-Platelet Therapy; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Male; Middle Aged; Perioperative Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Risk Factors	2022
Low incidence of hemorrhagic complications both during and after surgical procedures in patients maintained on prasugrel single antiplatelet therapy. Journal of neuroradiology = Journal de neuroradiologie, 2023, Volume: 50, Issue:1 Topics: Aspirin; Female; Humans; Incidence; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies	2023
Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population. Heart, lung & circulation, 2022, Volume: 31, Issue:8 Topics: Acute Coronary Syndrome; Aspirin; Australia; Clopidogrel; Hemorrhage; Hospital Mortality; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome	2022
Predictors of antiplatelet cessation in a real-world patient population undergoing non-cardiac surgery after PCI. International journal of cardiology, 2022, 10-01, Volume: 364 Topics: Aspirin; Drug-Eluting Stents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome	2022
Safety and Efficacy of Low-dose Prasugrel in the Endovascular Treatment of Unruptured Aneurysms in the Elders (≥ 75 Years). Clinical neuroradiology, 2023, Volume: 33, Issue:1 Topics: Aged; Aspirin; Embolization, Therapeutic; Endovascular Procedures; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Stents; Treatment Outcome	2023
Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study. European heart journal. Acute cardiovascular care, 2022, Sep-29, Volume: 11, Issue:9 Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Treatment Outcome	2022
Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN). Circulation journal : official journal of the Japanese Circulation Society, 2023, 05-25, Volume: 87, Issue:6 Topics: Aspirin; Drug-Eluting Stents; East Asian People; Everolimus; Hemorrhage; Humans; Japan; Percutaneous Coronary Intervention; Pilot Projects; Platinum; Polymers; Prasugrel Hydrochloride; Prospective Studies	2023
Sex-Related Bleeding Risk in Acute Coronary Syndrome Patients Receiving Dual Antiplatelet Therapy with Aspirin and a P2Y12 Inhibitor. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2023, Volume: 32, Issue:3 Topics: Acute Coronary Syndrome; Aged; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Treatment Outcome	2023
Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2023, Volume: 26 Topics: Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Eye; Hemorrhage; Humans; Japan; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rivaroxaban; Warfarin	2023
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies. Health technology assessment (Winchester, England), 2023, Volume: 27, Issue:8 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cohort Studies; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; ST Elevation Myocardial Infarction; Ticagrelor	2023
De-escalation from potent P2Y12 inhibitors to clopidogrel: an alternative to short DAPT duration in HBR patients? EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2023, Dec-04, Volume: 19, Issue:10 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Treatment Outcome	2023